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1. Introduction 
1.1 Definition of LUTS 
Lower urinary tract symptoms (LUTS) are a group of symptoms related to the 
prostate, urethra and bladder. LUTS have three components: voiding or 
obstructive symptoms, storage or irritative symptoms and post-micturition 
symptoms [1]. The voiding symptoms include hesitancy, which means a longer 
wait time for the stream of urine to start, weak stream, straining during 
micturition, dripping after urination is over or intermittent stream. The storage 
symptoms include urgency (feeling an urgent need to urinate), frequency (a short 
interval between requirement to urinate), nocturia (have to pass urine more than 
two times during the night and waking from micturition), and urge incontinence 
(a sudden, intense urge to micturition after an uncontrolled loss of urine) [2]. The 
post-micturition symptoms, which have received little attention, involve a 
feeling of incomplete emptying [3]. All three components have a potential 
burden on daily quality of life [4].  
 
Chronic conditions such as obesity, diabetes or hyperglycaemia, vascular 
hypertension or OSA (obstructive sleep apnoea) may be related with LUTS [5, 
6]. Especially based on epidemiologic studies, a relationship between metabolic 
syndrome and LUTS has been discussed in recent years, and is now widely 
accepted [7]. Lifestyle is also an important factor; heavy smoking, water intake 
during the night time, alcohol abuse or caffeinated drinks (tea, coffee, cola 
drinks), and even lack of physical activity can worsen storage symptoms [8, 9]. 
 
Voiding symptoms are most commonly caused by an obstruction at the outlet of 
the bladder base, which impedes the passage of urine [10]. Causes of this 
obstruction include an enlarged prostate gland and an increased smooth muscle 
tone in the prostate. In fact, benign prostatic hyperplasia (BPH) is one of the 
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most common causes of LUTS. However, there is no evidence of linkage 
between prostate volume and LUTS occurrence. Other causes of LUTS include 
neurological disorders (especially, in overactive bladder, neurological factors 
induce storage symptoms), stroke, taking medicine, drug abuse and mental 
illness [11]. 
 
Recently, the relationship between LUTS and metabolic syndrome (MetS) has 
become a popular topic of epidemiologic studies [5, 6, 12]. Before exploring this 
relationship, it is necessary to understand the definition of MetS. MetS is a term 
encompassing several parts that reflect abundant nutrition, sedentary lifestyle, 
and superfluous adiposity; these include obesity, insulin resistance, increased 
blood pressure and pro-inflammatory state [13]. MetS is regarded more as a 
cluster of different conditions than as a simplex disease, which means that the 
pathophysiological mechanism, treatment and prevalence are complex and 
numerous hormone levels are different from those of healthy people [14]. In 
other words, the risk of several diseases will increase under this disordered 
hormone level. MetS is related to an approximate doubling of cardiovascular 
system disorder risk and 5-fold increased risk for incidence of type 2 diabetes 
mellitus (T2DM) [15, 16]. In addition, current literature points out the important 
role of MetS-induced metabolic derangements in the development of benign 
prostate enlargement (BPE), which means an increased size of gland secondary 
to BPH. Patients who are overweighed have a higher risk of having MetS as a 
determinant of their prostate enlargement [17]. 
1.2 Epidemiology, etiology and nature history of LUTS 
An epidemiological study from 2010 predicted that an estimated number of 2.3 
billion individuals will be influenced by any types of LUTS [18]. Focusing on 
the LUTS patients’ distribution in 2018, Asia has the greatest absolute 
population of LUTS, followed by Europe, Africa, North America, and South 
America [18]. For Europe, the increasing LUTS population is mainly due to the 
enlargement of the overall ageing group [4]. Although these results are dynamic, 
  3 
they still shown that the worldwide burden of LUTS is increasing. In the next 
decade, the global expenditure of LUTS will keep rising [19]. Until now, 
epidemiologic studies have noted that a group of ageing-related diseases [20], 
cardiovascular disease and a combination of these disorder conditions, such as 
MetS, have a significant effect on LUTS [21].  
 
Furthermore, emerging clinical studies suggest that MetS may have a close 
relationship with BPE, which may be considered as the possible cause of LUTS 
[21]. Recently, strong evidence indicated that patients with MetS exhibited 
greater prostate sizes in the European population, suggesting that MetS 
participates in the development of BPH/LUTS [22]. Other etiologic factors, i.e. 
diet and lifestyle, which may lead to MetS, may also contribute to the process of 
BPH/LUTS [3]. Based on a multicentre and prospective study of a cohort 
database on US men, researchers suggested that the effect of MetS on 
BPH/LUTS pathogenesis may start in the early stage of adulthood, especially 
increasing body mass index (BMI), higher prostate volume and inflammation 
status of the prostate [23].  
 
The prostate gland has two growth periods. The first occurs in early puberty, 
when the prostate doubles in the size; the second is continuing slow growth for 
many years when the man is approximately aged 25 years [24]. This slow growth 
generally does not lead to problems until late in life; then, it can result in 
clinically relevant BPH [25]. Normally, BPH symptoms are rare in patients 
younger than 40 years old, but more than 50 % of men after retirement (60 years 
old) and 90 % of men in their 70s and 80s have at least any LUTS [26]. The 
burden of LUTS also needs full consideration. Recently, a novel study evaluated 
the burden of LUTS using severity and bother of the symptoms and suggested 
that for younger male patients, post-micturition dribble was the greatest burden, 
while in middle-aged and elderly men, urgency and nocturia were the most 
burdensome symptoms. In conclusion, the burden of LUTS increases with 
increasing age [27].  
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1.3 Pathogenesis of LUTS suggestive to BPH 
LUTS occur in male and female patients, and increase with age. In male patients, 
LUTS commonly occurs in parallel with BPH. Based on the anatomy of the 
lower urinary tract, the prostate is one of the accessory organs of the male 
reproductive system along with urethral glands, which is divided into three 
zones (peripheral, transitional and periurethral zone) [28]. BPH commonly 
occurs in the transitional and periurethral zone of the prostate. Enlargement of 
the prostate induces LUTS by two approaches: 1) as the so called “static 
component”, where the enlargement of prostate tissue induces compression of 
the urethra and finally bladder outlet obstruction (BOO); 2) the so called 
“dynamic component” describes an increased prostate smooth muscle tone, 
which contributes to urethral obstruction in parallel to the enlargement [29] 
(Figure 1). A clinical study suggests that as the age increases, the size of the 
prostate also increases and the prevalence of LUTS raised significantly with the 
age [30].  
 
Figure 1. Smooth muscle contraction and proliferation of prostate cells are the two key 
processes causing urethral obstruction and LUTS suggestive to BPH. Enlargement of the 
prostate induces bladder outlet obstruction, resulting voiding symptoms or even retention of 
urine. In advanced BPH, the risk of acute urinary retention (AUR) will be increased and 
medications are required in moderate-to-severe LUTS patients. Meanwhile, the alteration of 
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prostate smooth muscle tone is another key component of LUTS suggestive to BPH (All 
diagram materials are from https://www.123rf.com and https://www.vectorstock.com/).  
 
While the mechanisms, how BPH causes urethral obstruction and BOO are clear, 
the precise aetiology of BPH is still not completely clear. Certainly, there is an 
increased number of stromal and epithelial cells in the median lobe of the 
prostate, which may be due to proliferation or reduced programmed cell death 
[31-33]. Both of these mechanisms can lead to cellular accumulation and 
prostate enlargement [34, 35]. Furthermore, it has been suggested that androgens 
are vital to the process of BPH [36]. Nevertheless, dihydrotestosterone (DHT) is 
the active metabolite, which leads to prostatic growth. Testosterone is processed 
to DHT by the enzyme 5-alpha reductase (5-AR). However, the pathogenesis of 
BPH is not only a DHT-related mechanism [37].  
 
Androgen receptors located in the prostate contribute to the development of BPH 
[38, 39]. Recent in vivo data suggested that estrogens take part in 
androgen-related enlargement of the prostate, by sensitization for androgen [40]. 
It is generally accepted that BPH is mainly a stromal disease, but the foci of 
initiating events is still unclear [41]. As mentioned by several reports, chronic 
inflammation may contribute to the genesis of BPH [42]. Cytokines (IFN-α, IL-2, 
IL-6, IL-8 and IL-15) were identified and confirmed in the process of 
fibro-muscular prostatic growth [43], however, the precise role of these 
cytokines in the development of BPH remains unclear. 
 
It is widely accepted that a multifactorial aetiology contributes to LUTS 
suggestive of BPH [44]. Ageing is one of the most critical risk factors for 
development of LUTS [39]. The detailed molecular pathogenesis of BPH/LUTS 
has not been well established. However, in addition to age, inflammation, sex 
hormones, and metabolic factors have all been implicated [45]. 
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1.3.1 Age 
In younger male patients, LUTS can be caused by chronic prostatitis, which can 
lead to persistent dysuria and other symptoms that could cause men great 
concern. In clinical practice, younger men worry that dysuria could be caused by 
sexually transmitted diseases (STD) or cancer in genitourinary system [46]. 
Among elderly men, the most bothersome symptoms were urgency and nocturia. 
According to reports and patients’ surveys, middle-aged men who were near 
retirement had even patterns of experienced burden for each symptom, what 
makes sense as age has an important role in LUTS [27, 47]. Even though 
urgency was the most bothersome symptom in elderly men, patients have higher 
risks for serious complications from other diseases (hypertension, heart disease 
and diabetes) than from the urinary system. Urologists can predict the prostate 
volume via free prostate-specific antigen, total PSA and patient age [48]. There 
is an acclaim in considering BPH as a part of the process of ageing [49]. From 
the above, it is suggested that the global economic costs of LUTS/BPH treatment 
will continue to increase in the following decades [18, 50]. Because the options 
for treatment are still limited, the exploration of putative new targets and novel 
medications is necessary. 
1.3.2 Inflammation 
Chronic inflammation is a risk factor for fibrosis in many organs, such as liver 
and kidney [51]. High presence of chronic inflammation infiltrates in prostate 
specimens, including radical prostatectomy specimens and transurethral 
resection prostate strips [52]. Chronic inflammation may also be linked to BPH 
in pathological diagnosis [52]. Recently, a prospective study including 167 
autopsied prostates indicated that the presence and location of chronic 
inflammation were significantly associated with development of BPH; however, 
there was no association with prostate cancer [53]. Evidence from 
epidemiological studies implies that prostatic inflammation is related to the 
development of BPH, which tends to stimulate the continuous response to 
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metabolic stress signals [54]. A modest overall increased prevalence of 
BPH/LUTS in overweighed individuals is probably explained by the prostatic 
inflammation hypothesis. Currently, studies seek to estimate whether urinary 
cytokines reflect clinical attributes of LUTS suggestive of BPH [55]. The 
cytokines, including chemokine (C-X-C motif) ligand 1 (CXCL-1), CXCL-8, 
CXCL-10, C-C motif chemokine ligand 2 (CCL2), CCL3, and CCL5 in the 
recruitment of cluster of differentiation 3 T cell co-receptor (CD3+) and CD20+ , 
appear to take part in the process of LUTS by means of enhancing the chronic 
inflammatory response in prostate parenchyma [56, 57]. 
1.3.3 Sex hormones 
5α-reductase regulates the transformation of testosterone to DHT. Higher DHT 
expression parallels prostate enlargement. Treatment with 5α- reductase 
inhibitors (5ARI) has been reported to decrease prostate the volume in BPH, 
indicating the irreplaceability of DHT in the development of prostate growth 
[58]. Even though androgens are necessary for morphology and the basic 
function of the prostate, oestrogen also maintains vital biological functions. 
Estrogen plays a critical role in BPH development, and the prostate is widely 
considered as an estrogen target tissue [59, 60]. Furthermore, more details in the 
literature concluded that estrogens and selective estrogens receptor modulations 
directly and indirectly have effects on not only growth but also differentiation of 
the prostate [40]. Therefore, hormone research on therapeutic effects for BPH 
will be promising for the ageing male patients [61]. 
1.3.4. Metabolic factors 
Recent literature reported that patients with metabolic syndrome and related 
diseases, including obesity, hyperinsulinaemia, and insulin resistance, have a 
high risk to develop BPH/LUTS. The assumption of Vignozzi and colleagues 
suggested a plausible hypothesis, implying the importance of metabolic factors 
in the development of BPH. Their hypothesis drew attention to this linkage and 
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may be useful in exploring the relationship between metabolic syndrome and 
BPH [17, 61]. According to this theory, the step-stone of this process is chronic 
subclinical inflammation, which depends on the fat tissue of the patient and may 
be overlapped by metabolic factors, and indeed alters the sex hormone levels. 
The combined effect of these three hits reflect on disordered growth factors, 
which lead to the enlargement of prostate gland. In basic studies, non-genomic 
animal models of MetS, generated by feeding rabbits with high-fat diet for 12 
weeks, exhibited severe prostatitis-like syndrome, tissue remodelling and 
bladder dysfunction [17]. In addition, several inflammatory cytokines and 
chemokines secreted by prostate cells increased in animal models of MetS [17]. 
A study via metabolomics analysis in several male patients with LUTS 
suggested that the profiles of amino acids in the plasma may contribute to 
metabolic syndrome [62]. Meanwhile, increasing glutamate and decreasing 
arginine, asparagine, citrulline and glutamine are associated with LUTS in males 
[62].  
 
More recent evidence highlighted that obesity significantly raised the occurrence 
of BPH, and a relationship exists between diabetes and BPH [63]. Furthermore, 
MetS is thought to be associated with BPH/LUTS, likely through chronic 
inflammation. Cross-sectional and longitudinal studies tend to focus on vascular 
risk factors that appear to be related to the occurrence and degree of LUTS [64]. 
Similarly, moderate physical activity may reduce the risk of BPH [65]. Various 
mechanisms for this linkage have been discussed, such as reduced oxidative 
damage to the prostate cells and decreased sympathetic tone of prostate smooth 
muscle [65]. Because obesity appears to reduce the effect of dutasteride, these 
observations suggested that the development of new prevention strategies and 
treatment focus on weight loss and lifestyle, adiposity, and a individualized 
treatment of BPH according to patient comorbidities [66]. The mechanism of 
this effect might be related to the normalization of the various hormone levels in 
the serum of patients suffering with metabolic syndrome.  
  9 
1.3.5 Other urologic diseases associated with LUTS 
In clinical practice, it is observed that other diseases also produce LUTS, and the 
symptoms of several diseases are similar to LUTS. For example, LUTS 
associated with ketamine abuse has recently been a topic at least in Asia [67]. 
This syndrome has a clear cause and will cease if the ketamine use is suspended. 
However, urologists tend to ignore the true cause of this syndrome because the 
patients conceal their history [68]. Therefore, having a clear understanding of 
other diseases that produce LUTS is necessary and important for the following 
treatment.  
1.3.5.1 Overactive bladder (OAB) 
Patients with LUTS due to OAB likely suffer for urinary incontinence (UI) [69]. 
OAB causes a subset of storage LUTS defined by the International Continence 
Society as urgency, usually with frequency and nocturia [70]. Notably, male 
patients who are suffering with LUTS associated with OAB are more likely to 
respond to antimuscarinic therapy than to α1-blockers [71]. This points to the 
divergent mechanisms underlying the voiding symptoms caused by BPH, and 
the storage symptoms caused by OAB. 
1.3.5.2 Bladder tumour 
In a recent, retrospective cohort study, the investigators demonstrated the 
linkage between LUTS and occurrence of initial bladder tumour [72]. Tumours 
in the lower urinary tract may also cause LUTS [19]. For instance, a case report 
showed that soft tissue chondroma located in the bladder and caused LUTS and 
nocturia [73]. Tumours in the lower urinary tract may cause compression in 
urethra or impair the bladder outlet, which will finally result in obstructive 
LUTS resembling those caused by bladder outlet obstruction in BPH [4]. 
However, in such patients, the cancer and tumour burden will be most 
bothersome, and therapy will focus on cancer treatment [74]. 
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1.3.5.3 Spinal cord injury 
Neurogenic lower urinary tract dysfunction is a very common and 
under-assessed disease, which affects the quality of life of patients and is a 
consequence of many diseases, such as stroke, Parkinson disease and spinal cord 
injury (SCI) [75-77]. SCI damages the descending motor and ascending sensory 
pathways, preventing normal bladder function and urethral control [77]. All of 
these lead to LUTS. 
1.3.5.4 Prostate cancer 
The linkage between prostate cancer and LUTS still needs more support from 
clinical data. The debate about this relationship is currently focused on PSA 
testing. The PSA test is frequently used for confirming prostate cancer [78-80]. 
However, the test’s limitation may cause false results and over diagnosis. In a 
cohort study based on a large population, development of LUTS was strongly 
related to localized prostate cancer, but there was no association with fatal 
prostate cancer (defined as who suffering from regional or distant metastases). In 
other words, monitoring of LUTS in the early stage of cancer is not helpful 
because the urinary symptoms are not only induced by prostate cancer [81]. 
1.3.5.5 Chronic pelvic pain syndrome 
Different groups of symptoms have been regarded as chronic pelvic pain 
syndrome, including chronic, abacterial prostatitis, interstitial cystitis, and 
painful bladder syndrome [82]. Some studies suggested that the prostate factors 
may be important in the pathogenesis of chronic pelvic pain syndrome, which 
also plays a role in LUTS suggestive of BPH [83]. For instance, approximately 
30 % of men who diagnosed with chronic prostatitis, also report symptoms 
relative to pelvic pain syndrome [84].  
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1.3.6 Genetic determinants 
Aetiologic studies on BPH/LUTS appear difficult and complex because various 
processes participate in prostate enlargement and are suggestive of LUTS, such 
as prostatic stromal cell growth and altered smooth muscle tone. A series of 
genetic alterations may contribute to BPH/LUTS [18]; however, there is a 
pressing need for improved understanding of the relationships between the 
symptoms and target genes [85]. Nevertheless, patients with large prostates are 
susceptible to serious LUTS; however, some patients with the same prostate 
volume may not experience bothersome LUTS and do not require any 
medication [86]. Therefore, genetic determinants appear possible, and a 
genome-wide association study (GWAS) is necessary for LUTS research. 
Recently, a GWAS study based on 5000 subjects reported that GATA3 could be 
a promising candidate gene for BPH/LUTS research. In BPH/LUTS populations, 
the expression of GATA3 is marginally increasing, which means that this gene 
may contribute to the development of BPH/LUTS [8]. Although this result is still 
preliminary and does not reach a significant level for GWAS, it could be 
regarded as a new vision for exploring the aetiological mechanism of 
BPH/LUTS in the future. 
1.4 The role of MetS in LUTS 
The importance of metabolic syndrome such as diabetes and obesity in clinical 
work increased. The morbidity and mortality associated with metabolic 
syndrome are expensive and represent a serious burden to numerous patients 
[87]. Recent studies reported that metabolic syndrome probably plays a role in 
the development of LUTS [23, 88, 89]. MetS is a group of diseases and states, 
including obesity and pro-inflammatory state. Behind these various patterns of 
disease, the main pathophysiology is insulin resistance. There are several factors 
surrounding insulin resistance that affect the development of metabolic 
syndrome and related target organs such as liver, kidney and prostate. 
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Furthermore, MetS may induce the metabolic stress to prostate cells and also 
play an important role in LUTS suggestive to BPH. 
1.4.1 Obesity and LUTS 
A case-control study showed that compared with normal BMI subjects, men who 
were obese had medium higher odds of suffering LUTS [90]. Another clinical 
population-based cohort trial suggested that the risk of developing LUTS 
increased with waist circumference and BMI in women [91]. Interestingly, 
physical activity was a protective factor for obese patients. The researchers used 
daily walking time as an evaluation index and found that the men who walked 
daily had decreased chances of developing LUTS [22]. Currently, the 
mainstream hypothesis is that obesity has a linkage with LUTS in ageing men, 
but the mechanism of this association is still unclear [92-95]. 
1.4.2 Insulin resistance in smooth muscle 
Various related pathways may explain the association of insulin resistance (IR) 
and BPH/LUTS. The first could be that the state of sympathetic nerve activity is 
upregulated [23]. Furthermore, disordered insulin levels lead to increased 
endothelin levels in vascular smooth muscle cells [96]. The increased nerve 
activity and overexpressed endothelin may lead to higher prostate smooth 
muscle tone [97]. At the same time, higher insulin levels may induce a chaotic 
trophic hormone state, which probably increases the prostate volume. Abnormal 
regulation of the insulin-like growth factor (IGF) axis has been reported in the 
development of BPH and the onset of prostate cancer [98, 99]. 
 
The pathogenesis of BPH includes a disruption of the balance of hormonal and 
other growth factors, such as IGF, leading to cellular proliferation of prostate 
stromal cells and to decreased extent in the epithelial regions of the prostate [99]. 
IGF and its binding proteins (IGFBPs) may contribute to the aetiology of 
BPH/LUTS [100]. Not only endogenous and exogenous hormones but also 
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genetic profiles affect expression level of circulating IGFs and IGFBPs. 
Furthermore, IGFBP3 has unique growth-inhibitory and pro-apoptotic actions. 
IGFBP3 is widely reported to inhibit angiogenesis by means of reducing 
vascular endothelial growth factor (VEGF) [99]. In a case-control study of BPH 
patients, which recruited 1454 individuals, researchers suggested that the risk of 
clinical BPH showed a positive relationship with the IGFI/IGFBP3 ratio, while 
clinical BPH risk was also related to IGFBP3 [101]. Moreover, this study 
depicted that modest associations between BMI and IGF contribute to the risk of 
development of BPH. Obese men in the upper 25 % of IGFI/IGFBP3 ratio had 
almost twice the risk of clinical BPH compared to those in the lower 25 % [102].  
 
Insulin resistance or insulin sensitivity are very common in individuals with 
abnormal metabolic activity, and these alter not just the β-cells of pancreas but 
also the target organs [103]. In practice, obesity could be the impetus of insulin 
resistance, suggesting that ageing male patients suffering from diabetes and 
obesity at the same time will be the susceptible group of BPH/LUTS [104].  
1.4.3 Pro-inflammatory molecules in LUTS 
Several inflammatory factors are elevated in the metabolically abnormal 
individuals, such as C- reaction protein (CRP), tumour necrosis factor (TNF), 
IL-6 and IL-8. The main reason is that obesity induces cytokine release in 
parallel to macrophage infiltration [105]. This cytokine and inflammatory cell 
increase could maintain a pro-inflammatory state in the prostate [106]. 
Inflammatory infiltrates were commonly observed in prostate tissue. Cytokines 
IL-6 and IL-8, for example, are raised in MetS and may lead to inflammation in 
the development of BPH/LUTS; they can also be secreted by prostate stromal 
cells with cytokine stimulation or recruitment by inflammatory cells such as 
macrophages, and both result in enlargement of prostatic tissues. Furthermore, 
IL-8 could be a promising biomarker for BPH/LUTS [107]. 
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1.4.4 Environmental factors that contribute to LUTS 
In many patients, MetS becomes manifest in diseases such as obesity, 
hypertension, dyslipidaemia and diabetes. Individuals with MetS may be 
exposed to environmental stressors such as diet [108]. A twin study suggested 
that environmental factors, including diet, are associated with health in urinary 
system [109]. For instance, low-fat diets, grilled meat, vitamins, protein and 
vegetables are important factors in the development of BPH/LUTS [9]. 
Considering the substantial environmental effects, future researches tend to  
focus on identifying specific environmental risk factors that cause LUTS [9].  
1.5 Pharmacological treatment for LUTS 
For many years, surgery has been regarded as the standard therapy for relieving 
BPH/LUTS. In recent years, the new medical therapy has changed the guidelines 
of BPH/LUTS management, and moved surgery, mainly in the form of 
transurethral resection of the prostate, or laser procedures to the second line. In 
the cases of non-bothersome LUTS, watchful waiting is an option for the 
patients who have few risks of acute urinary retention (AUR) and other 
complications [4].  
 
For individuals with moderate-to-severe LUTS, α1-adrenoceptor antagonists 
(α1-blockers) represent the mainstream medical therapy for BPH/LUTS [19]. 
Furthermore, patients suffering from moderate-to-severe LUTS and an enlarged 
prostate (prostate volume more than 40 mL) can obtain 5ARIs for supplement 
[110]. They can slow down or prevent the disease progression with regard to 
AUR and requiring for further surgery treatment. BPH/LUTS is accepted as a 
unique condition that influences the quality of life (QoL) [111]. However, 
non-selective α1-blockers should be carefully applied in elderly patients in case 
of the occurrence of orthostatic hypotension [112]. For instance, the first 
non-selective α1-blockers phenoxybenzamine was reported to be effective in 
BPH, but has several side effects, which include tiredness, dizziness, nasal 
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stuffiness, and hypotension [113]. After that, long-acting selective α1-blockers 
are recommended by the American Urological Association (AUA) and 
European Association of Urology (EAU), which are effective and show better 
tolerability than non-selective α1-blockers [114]. However, long-acting selective 
α1-blockers may still damage sexual ability [4]. Moreover, LUTS patients 
without valid and stable treatment may have higher risk of renal insufficiency 
and chronic kidney disease (CKD), which may threat life [115]. Therefore, it is 
important to keep a high patient compliance of pharmacology treatment. The 
adherence to drug therapy in BPH/LUTS is based on the balance between 
efficacy and side effects. Several drug classes are available for medical treatment 
of LUTS, which were approved based on clinical trials and preceding preclinical 
research [19]. 
1.5.1 Monotherapy  
1.5.1.1 α1-blockers  
1.5.1.1.1 Mechanism of action  
Generally, the effect of endogenously released noradrenaline on smooth muscle 
cells in the prostate is inhibited by α1-blockers. α1-blockers have been suggested 
to decrease prostate smooth muscle tone and BOO [4]. Smooth muscle is a major 
cellular constituent of the prostatic stroma in BPH [116]. According to the high 
expression of α1–adrenergic receptors in the human prostate smooth muscle, the 
adrenergic innervation in prostatic function is important for development of 
LUTS suggestive to BPH [117]. In controlled phase III clinical studies, obvious 
decreases in International Prostate Symptom Score (IPSS) were observed, 
parallel with improvements in maximum flow rate (Qmax) of approximately 3 
points relative to placebo [112]. α1-blockers improve the situation of many 
patients, as evidenced by numerous clinical studies. Consequently, they emerged 
to the most important medication for treatment of LUTS suggestive of BPH. 
Nevertheless, α1-blockers have almost no effect on bladder outlet resistance, and 
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obstruction is barely improved by α1-blockers. Thus, other mechanisms of action 
than smooth muscle relaxation in the prostate may also be relevant. Outside the 
prostate (e.g., urinary bladder and/or spinal cord), α1-adrenoceptors and 
α1-adrenoceptor subtypes (α1b- or α1d-adrenoceptors) may play a role as 
mediators of various effects [117] (Figure 2). In blood vessels, other 
non-prostatic smooth muscle cells, and even the central nervous system, 
α1-adrenoceptors may regulate adverse events [118].   
 
Figure 2. According to the receptor distribution in the lower urinary tract, the α1a-adrenergic 
receptor subtype is primarily located in the prostate and bladder neck, with a few others within 
the bladder. Therefore, the α1a-adrenergic receptors subtype predominates in prostate tissue and 
regulates smooth muscle tone. 
1.5.1.1.2 Pharmacology of α1-blockers 
Various pharmacologic therapies are the first choice for treatment of BPH/LUTS. 
Normally, α1-blockers are the preference for the patients. The usage of 
α1-adrenergic blockers is based on targeting prostate α1a-adrenergic receptors. 
Physicians pick up and prescribe several alpha-blockers in real-life clinical 
practice [119]. Three different subtypes of α1-adrenergic receptors have been 
characterized: α1a-adrenergic receptors, α1b-adrenergic receptors, and 
α1d-adrenergic receptors, which differ in amino acid composition [119]. The 
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α1a-adrenergic receptors subtypes predominate in prostate tissue and regulate 
smooth muscle tone. Additionally, expression of the α1a-adrenergic receptors 
subtype is raised in BPH prostatic tissue compared to non-BPH prostatic tissue. 
In non-BPH prostatic tissue, the proportion of α1a to α1b to α1d receptors was 
63:31:6; in BPH tissue, the ratio was 85:14:1 [118, 120]. Pharmacologic 
urologic selectivity of α1-blockers relies on the binding affinities to these 
subtypes. Tamsulosin is 3 times more selective for the α1a-adrenergic receptors 
subtype than for the α1b- and α1d-adrenergic receptors [121]. Naftopidil has a 
three times greater affinity for the α1d- than for the α1a-adrenergic receptors 
[122]. Silodosin is highly selective for α1a-adrenergic receptors, with a 162 times 
greater affinity than for α1b-adrenergic receptors and an approximately 50 times 
greater affinity than for α1d-adrenergic receptors [123]. Alfuzosin is also a 
selective α1-blocker, which provides quick and continuing relief of LUTS [124]. 
1.5.1.2 5ARIs 
1.5.1.2.1 Mechanism of action 
5-Alpha-reductases are enzymes that regulate the conversion of testosterone into 
dihydrotestosterone (DHT). In the 1970s, the critical role of the 5AR-dependent 
testosterone to DHT transformation in the development of BPH was claimed 
[125] (Figure 3). Following animal experiments and phase III clinical studies, 
finasteride (Proscar) and dutasteride (Avodart) were used in the therapy of BPH 
with LUTS. In the clinical studies, 5ARIs decreased prostate volume by 20 % to 
30 % and also reduced scores of LUTS, while the risk of AUR and surgical 
treatment within 3 to 6 months was also reduced [126]. These highly selective 
inhibitors do not directly block the activity of testosterone and do not affect the 
circulating testosterone concentration. The effects of these 5ARIs are limited to 
the target organ, including prostate and scrotal skin, which lead to local 
production of DHT [127, 128]. 
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Figure 3. In the prostate cells, serum testosterone is converted to dihydrotestosterone, which 
relies on the 5ARs. There are two main types within the prostate cell (type 1 and type 2) [126]. 
Type 2 is the predominant form in prostate cells, but type 1 is still expressed. DHT enhances 
prostatic cell proliferation and suppresses apoptosis, i. e. blocks the process of programmed cell 
death.  
1.5.1.2.2 Pharmacology of 5ARIs 
According to available clinical evidence, finasteride monotherapy is regarded as 
an option in patients with medium to severe LUTS and a high prostate volume 
(>40 mL) [129]. Furthermore, FIN is also used to treat patients who do not have 
prostate enlargement [130]. Unlike finasteride, which inhibits 5AR isoform type 
II, dutasteride inhibits not only 5AR isoform type II but also type I [126]. 
Dutasteride has been called a dual inhibitor, and unlike finasteride, dutasteride 
has effects in patients with prostate volume ranging from 30 mL to 40 mL. Side 
effects such as erectile dysfunction (ED), decreased libido and ejaculatory 
disorders (EjDs) appear to be the most common complaints in clinical work, 
which result from 5ARIs [4]. Therefore, open discussion of the sexual side 
effects with patients who need this therapy is necessary and important [126]. 
1.5.1.3 Muscarinic receptor antagonists 
Muscarinic receptor antagonists are not exclusive treatments for LUTS 
suggestive of BPH. In fact, their use in BPH is even argued by theoretical risks 
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that post-void residual urine may increase by such drugs, and detrusor inhibition 
may cause voiding difficulties and life-threatening acute urinary retention [131]. 
Muscarinic receptor antagonists are approved for treatment of OAB and storage 
symptoms [131]. In the past, muscarinic receptor antagonists were mostly 
examined in women because it was accepted, that male LUTS are mainly related 
to prostate disorder; therefore, physicians believe that male patients should be 
treated with prostate-specific medications [132]. Nevertheless, usage of 
muscarinic receptor antagonists in male patients suffering from LUTS 
suggestive of BPH and with symptoms of OAB has become increasingly 
relevant in the last decade. However, because of the absence of studies on the 
long-term effects of muscarinic receptor antagonists on LUTS, the prescription 
of muscarinic receptor antagonists should be cautioned [133]. Available 
medicines are fesoterodine, darifenacin, propiverine, oxybutynin, tolterodine, 
solifenacin, and trospium chloride.   
1.5.1.4 β3-adrenoreceptor agonists 
In the urinary bladder, β3-adrenoreceptor agonists are thought to cause relaxation 
of the bladder and prevention of urination [87], especially by relaxation of the 
detrusor [50]. Based on the effect on the detrusor, the application of 
β3-adrenoceptor agonists on OAB has been established [134]. β3-adrenoceptor 
mRNA is expressed in detrusor, and β3-adrenoreceptor agonists were reported 
inhibited calcium oscillation in detrusor, which reduces detrusor contraction 
[135]. Functionally, the β3-adrenoreceptor appears to be a promising target for 
pharmaceutical agents. According to preclinical studies, other evidence shows 
that the agonists of β3-adrenoceptor is predominant over other β-adrenoreceptors 
and has the ability to reduce the detrusor contraction and good tolerability for 
OAB patients [136]. In clinical practice, mirabegron 50mg is the first licensed 
β3-adrenoreceptor agonists for treating OAB patients and especially focus on the 
symptoms including micturition frequency and urgency [137]. 
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1.5.1.5 PDE5 
In mammalian species including human beings, the whole lower urinary tract 
expresses phosphodiesterase type 5 (PDE5) [138, 139]. Immunohistochemical 
(IHC) results depicted that PDE5 is localized in the lower urinary tract blood 
vessels, endothelial cells and smooth muscle cells. Furthermore, in in vitro 
studies, PDE5 inhibitors relaxed the contraction of isolated prostate and bladder 
neck strips. Based on this, PDE5 inhibitors were recommended by the European 
Association of Urology for treating LUTS suggestive to BPH [19]. Uniquely, 
PDE5 is expressed in human prostatic stromal cells, which are different from the 
lower urinary tract blood vessels. Several clinical evidences suggested that 
PDE5 inhibitors reduced the international prostate symptom score (IPSS) 
compared to the placebo. Based on a recent meta-analysis, monotherapy of 
PDE5 inhibitors was similar effective to α1-blockers on reduction of postvoid 
residual urine (PVR) and IPSS [140]. According to guidelines for treatment of 
male LUTS, tadalafil  is recommended and reaches an clinically objective 
improvement of LUTS, which is higher than that of placebos [141].   
1.5.1.8 Herbal medicine  
According to recent reports, in western countries, the investment and expenses in 
all types of BPH medications are rapidly increasing [19]. However, in eastern 
Asia, such as Japan and China , the expenditures of BPH therapeutics are still 
lower than in the western countries [142]. Several interactional studies suggest 
that plant extracts and herbal medicine occupy a considerable part of BPH 
pharmaceutical marketing [143, 144]. Serenoa repens (SeR), the most reported 
plant medicine for LUTS treatment, has been indicated by a multicentre study to 
significantly reduce the prostate volume in patients with BPH [145]. Gravas et al. 
suggested that SeR significantly reduced prostate inflammation in terms of 
histological parameters [145]. Morgia et al. suggested that SeR improved the 
slightly Qmax and IPSS in patients with moderate-severe LUTS suggestive to 
  21 
BPH [146]. Nevertheless, they are not recommend by the guidelines of EAU or 
AUA [19, 147]. 
1.5.2 Combination therapies 
1.5.2.1 Combination of α1-blockers with 5-ARIs  
The most promising combination therapy is α1-blockers with 5-ARIs, as 
demonstrated by several studies all over the world. According to Füllhase et al., 
some of these studies argued that the combination of α1-blockers with 5-ARIs 
has been discussed thoroughly and scientifically for the groups in different ages 
[120, 130]. Generally, patients with large prostates (volume more than 40 mL), 
who have a high risk of complications, are the group with the largest profit from 
this combination therapy. 
 
After considering the clinical index (IPSS, Qmax, and prostate volume), the effect 
of different treatment options was ranked by the physicians. The most 
recommended is combination therapy. A high-level clinical trial acclaimed that 
α1-blockers and 5-ARI combination increased Qmax twice than α1-blockers 
monotherapy [148]. In June 2010, a one set oral medication of dutasteride and 
tamsulsion (Jalyn, GSK, U.K.) was examined by the US Food and Drug 
Administration for use in BPH patients with enlarged prostate. The potential of 
combination therapy of α1-block with 5-ARIs is apparent. 
1.5.2.2 Combination of antimuscarinics and α1-blockers 
Male LUTS are often attributed to BOO suggestive of BPH and are treated with 
drugs targeting the prostate, including α1-blockers and 5α-reductase inhibitors. 
However, these agents may not effect in many male patients with LUTS 
adequately, especially men with mixed LUTS, including voiding LUTS and 
storage LUTS. Antimuscarinics could be an alternative option for patients who 
are suffering with OAB symptoms despite treatment for prostatic enlargement. 
Therefore, Kaplan et al. suggested that antimuscarinics appear to be a powerful 
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and safe option for urgency, frequency, urgency urinary incontinence, and 
symptoms associated with OAB in male patients who are not suffering clinically 
significant bladder outflow obstruction, but antimuscarinics alone are not 
approved for the treatment of BPH. There is clinical evidence that 
antimuscarinics alone would increase the risk of AUR [149]. 
1.5.2.3 Combination of α1-blockers and β3-adrenergic receptor 
agonists 
The β3-adrenergic receptor plays a critical role in bladder smooth muscle 
relaxation [150]. Mirabegron, a β3-adrenergic receptor agonist, is a first-line 
medication launched in 2011 that can be applied for the treatment of OAB 
symptoms. The side effects, including dry mouth and constipation, are lower 
with mirabegron than with anticholinergic drugs [4]. A randomized, controlled 
study reported that patients who have already received treatment of α1-blocker 
can still benefit from the add-on treatment of mirabegron (50 mg per day) [151]. 
50 % to 75 % male LUTS patients reported OAB symptoms, so that 
pharmacotherapy with an α1-blocker alone could not reduce OAB symptoms 
[152]. Furthermore, the β3-adrenergic receptor may increase bladder capacity 
and extend micturition interval [153]. These data suggest that combination of 
mirabegron with routine α1-blocker management is an option to improve the 
QoL. 
1.5.2.5 Combination of 5-ARIs and PDE5Is  
According to clinical research, combination of different types of BPH treatment 
is superior to single management by α1-blockers or 5-ARIs. Looking into the 
clinical practice patterns, 5-ARIs are commonly prescribed drugs for LUTS 
suggestive to BPH [119, 154], which decrease the development of BPH [155]. 
Combination of 5-ARIs with PDE5Is has been tested recently and the effect was 
estimated by several randomized controlled trials [126]. The combination 
therapy improves the effect in terms of clinical LUTS suggestive to BPH, 
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because PDE5Is principally inhibit contraction, and are applied for rapid 
symptom improvement [156]. Roehrborn et al. launched an international, 
randomized, double-blind, parallel study about the combination treatment of 
finasteride and tadalafil (both are 5 mg daily) [157]. Significant LUTS 
improvement was observed, and the effect lasted longer than finasteride 5 mg 
alone, which means that the combination effect could improve treatment 
outcomes more than monotherapy. Furthermore, decreased side effects and 
increased tolerance and safety were mentioned in this study. Therefore, for the 
treatment of LUTS secondary to the BPH, a combination strategy is worth 
applying to patients suffering medium and severe symptoms. 
1.5.3 Limits of current therapies 
First-line medical therapy for LUTS secondary to BPH in middle-aged male 
patients includes α1-blockers and 5α-reductase inhibitors (5ARIs) [157]. 
α1-blockers, as the mainstream option, decrease the IPSS and increase Qmax (a 
reduction of IPSS by 30-40 % and increase of Qmax about 20-25 %); they also 
improve QoL [4]. Six α1-blockers have been reported for the medication therapy 
of LUTS secondary to BPH: terazosin, doxazosin, tamsulosin, naftopidil, 
alfuzosin, and silodosin. All successfully improve voiding LUTS vs. placebo [19, 
120]. However, comparable effects of placebo were observed [158].Based on 
clinical studies, these α1-blockers reduce IPSS and improve Qmax by not more 
than 50 %, meanwhile placebos may lead to improvements around 30 % [4]. 
Additionally, α1-blockers present little effect on decreasing the prostate volume, 
or preventing the occurrence of AUR or the requirement for surgery [159].   
The limitations of α1-blockers may result from various causes, and raise the 
demand of new medications with higher efficacy on treating LUTS suggestive to 
BPH. 
 
5-ARIs appear to be only effective in men with moderate to severe LUTS; for 
patients with prostate volume < 40 mL, 5-ARIs might not be more useful than 
placebo [155]. The short-term efficacy of 5-ARIs on symptom reduction is slow, 
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generally needing three months [126]. Furthermore, monotherapy is not 
sufficiently effective for patients with moderate-to-severe LUTS after the first 
round of therapy [160]. The risk of symptomatic progression, which is the 
primary aim of 5-ARI administration, can be reduced by not more that 35-40 % 
by monotherapy, and to maximally 66 % by combination therapies [161]. 
Moreover, based on a population-based cohort study, the discontinuation rate for 
5-ARIs is high, peaking up to 70 % of patients who do not continue their 
medication after 1-year treatment [162]. Many patients stop taking medications 
because the effect of 5-ARIs is lower than expected or because they do not 
understand that the clinical improvement may need 3-6 months [163]. 
 
Sexual adverse effects, including decreased libido, are the most common 
complications resulting from the use of 5ARIs and have been documented to 
range from 0.9 to 38 % [164]. Some patients may stop taking medication because 
of anxiety of their sexual function. Studies of androgen receptors in animal 
models, which were based on cavernosal tissue of rats, suggested that reduction 
of DHT levels in the prostate may cause the effects of 5ARIs on sexual function 
[110]. Finasteride changes the levels of DHT in serum, which may lead to 
erectile dysfunction by decreasing levels of nitric oxide (NO) and reducing nitric 
oxide synthase (NOS) activity in the corpus cavernosum  [165]. It is suggested 
that at comparative high doses, finasteride impaired erectile function by causing 
NOS activity disorder in the penis [149].  
 
From the psychiatric side, low-dose finasteride (5-ARIs) may produce 
depression symptoms[119]. There is a demonstrated link between levels of 
androgen (low free testosterone) and depression, as depressive symptoms were 
found in men with prostate cancer treated with androgen deprivation, but the 
exact mechanism remains unknown [166]. Roemer et al. published research on 
the effects of finasteride on mice and found that 5ARI administration reduced 
neurogenesis of the hippocampal area, which was associated with depression 
[167].  
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The studies on PDE5 inhibitors are merging; however, in long-term application 
(more than 1 year) the tolerability and safety of PDE5 inhibitors remains unclear, 
and their effects on reducing prostate size and slowing disease progression still 
need to be researched [168]. The risk of adverse drug reactions (ADRs) resulting 
from PDE5 inhibitors is obviously dose-dependent. Additionally, the most 
common ADR is headache, reported in >10 % of patients who are managed with 
long-term PDE5 inhibitors [139]. Other ADRs, including dizziness, dyspepsia, 
flushing, rhinitis or nasal congestion, have also been reported from clinical 
studies[156].  
 
In conclusion, to overcome these disadvantages and side effect of commonly 
used treatments for BPH, novel BPH therapies should be considered, and the 
deep mechanism should be understood. The efficacy of current medications is 
limited, even despite the widespread application of some drugs. Considering the 
disappointing continuation rate of current medications, other options for patients 
could be recognized in the future. 
1.5.4 Novel compounds in pathophysiology and experimental therapy 
of LUTS  
A number of studies introduced the concept that many more signaling pathways 
than previously known may promote prostate smooth muscle contraction and the 
development of prostate enlargement. Many attempts have been made with the 
purpose of providing novel solutions for LUTS suggestive of BPH, including 
approaches based on several GTPases and kinases [117, 169-172]. Taken 
together, it is becoming increasingly obvious that there is a much higher 
complexity than previously assumed which accounts for the mechanisms 
underlying prostate smooth muscle contraction. In recent years, an increasing 
number of new compounds have been identified as possible potential candidates 
for putative new therapy options for LUTS suggestive to BPH, and some are to 
be further explored for clinical applications. 
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1.5.4.1 G protein-coupled receptor kinases 2 and 3 (GRK2/3)  
GRK2/3 are expressed in the human prostate [173, 174]. It has been proposed 
that GRK-mediated receptor phosphorylation may critically regulate activation 
of α1-adrenoceptors in the human prostate. GRK2/3 are supposed to cause 
phosphorylation of β2-adrenoceptors without involving protein kinase C (PKC) 
[169]. Furthermore, in the human prostate, GRK-mediated receptor 
phosphorylation may also important to connect α1-adrenoceptors to β-arrestin-2 
and other accessory binding partners [174]. α1-adrenoceptors regulate prostate 
smooth muscle contraction, meanwhile, activation of intracellular signalling 
pathways by G-proteins is require also for other G-protein-coupled receptors; 
and receptor-mediated smooth muscle contraction appears to connect with 
GRK2/3-mediated receptor phosphorylation [173]. In human prostate smooth 
muscle, CMPD101, a selective GRK2/3 inhibitor, inhibits α1-adrenergic, 
neurogenic, and non-adrenergic contractions. This reagent may be an interesting 
compound in this context, also regarding translational aspects of clinical studies 
[173].   
1.5.4.2 Polo-like kinases (PLKs) 
Polo-like kinases (PLKs), a group of serine-threonine kinases, have been widely 
associated with promotion of proliferation and also regulation of the cell cycle. 
In airway and vascular smooth muscle contraction, recent studies suggested that 
PLK1 plays a critical role [175]. It has been suggested that prostate smooth 
muscle contractions were decreased after treatment with several PLK inhibitors 
[176]. Endothelin-1 and thromboxaneA2 induced contractions were not 
sensitive to PLK inhibitors, which depicted a divergent regulation of adrenergic 
and non-adrenergic prostate smooth muscle contraction by PLKs [176]. It is 
possible that, in the hyperplastic human prostate, PLK1 promotes α1-adrenergic 
smooth muscle contractions [176].  
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1.5.4.3 LIM kinases 
Based on cardiovascular disease studies, a promising role appears possible for 
LIMKs, as it has been reported that α1-adrenoceptors in the cardiovascular 
system lead to phosphorylation of cofilin via LIMKs activation [177]. Recently, 
a study using LIMK inhibitors demonstrated that LIMK inhibitors reduce 
contractions of human prostate tissues [178]. According to these results, in the 
prostate, LIMKs inhibitors inhibit smooth muscle contraction. In conclusion, 
LIMKs might be relative to bladder outlet obstruction and urethral obstruction in 
BPH [178]. 
1.5.4.4 Rac GTPase inhibitors 
RhoA, a member of the superfamily of small monomeric GTPases plays an 
important role in contraction of smooth muscle [179]. According to recent 
studies, Rac (as another monomeric GTPase) regulates relaxation of airway 
smooth muscle, and also vascular smooth muscle [180]. In the human prostate, 
recent evidence suggested that all three isoforms of Rac are expressed in human 
prostate tissue, and inhibition of Rac GTPases decreased proliferation of prostate 
stromal cells and inhibited prostate smooth muscle contraction [181]. Taken 
together, Rac may be a promising new target for treatment of LUTS suggestive 
to BPH.  
1.5.4.5 Src family kinases (SFKs) 
SFKs, non-receptor tyrosine kinases, involved in the regulation of central 
cellular functions, such as regulation of the cell cycle and promotion of 
proliferation of different cell types [182]. Furthermore, based on studies about 
airways, gastrointestinal tract, and uterus SFKs inhibitors play a role in  smooth 
muscle contraction in these organs [183]. Recent evidence showed that SFKs 
inhibitors affect the organization of actin filaments in prostate smooth muscle, 
which are required contraction. In line with this, SFKs inhibitors also inhibited 
smooth muscle contractions of human prostate tissues, and, in parallel, inhibited 
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the proliferation of prostate stromal cells [170]. These finding suggest that SFKs 
could be a possible target for inhibiting the smooth muscle contraction and 
proliferation at the same time. 
1.5.4.6 Focal adhesion kinase (FAK) 
Activation of FAK could be important for α1-adrenoceptor-mediated contraction 
[184, 185]. In previous studies, a role of FAK for contraction of bladder smooth 
muscle has been reported [186]. Using a prostate cell culture model and human 
prostate tissues, it has been recently suggested that application of FAK inhibitors 
reduces prostate smooth muscle tone [187]. Importantly, FAK may be critical for 
the pathogenesis of LUTS suggestive to BPH. 
 
1.6 Generally studies on development of Ghrelin system 
1.6.1 History of Ghrelin   
Kojima et al. proposed ghrelin as a new gastric hormone and clarified its 
function and structure [188]. The name of this hormone is a metaphor of growth, 
as abundant studies merged and suggested that this newly discovered hormone 
leads to the growth hormone (GH) release [189]. Ghrelin, a 28 amino acid 
acyl-peptide, is esterified with octanoic acid on Serine 3. GHSR-1a activation is 
necessary for acylation; however, it is widely accepted that des-acyl ghrelin is 
far more abundant than acyl-ghrelin [190]. Nevertheless, the main function of 
des-acyl ghrelin remains unknown. In 2002, Baldanzi et al. demonstrated the 
function of des-acyl ghrelin in cardiomyocytes and endothelial cells, suggesting 
that the des-acyl ghrelin could be a survival factor in the cardiovascular system 
[191]. After that, discussions around the ghrelin and des-acyl ghrelin are 
continuous, and they appear to be a promising pharmacologic topic. 
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1.6.2 Various forms  
Generally, two forms of ghrelin have been reported in the human stomach. The 
first is the acylated ghrelin (AG), with the n-octanoylated serine at position 3, 
which is widely studied [192]. The second is the des-acyl ghrelin (DAG), 
produced by the other splicing of the ghrelin gene [193]. Additionally, as 
mentioned before, acylation is common and necessary for GH release in many 
processes involving the ghrelin system [190]; DAG is the usual form (plasma 
desacyl-ghrelin accounts for 75 % of total circulating ghrelin) in the ghrelin 
system [194, 195]. Furthermore, in human plasma and the stomach, some minor 
forms of ghrelin are expressed [196].  
 
Acyl-transferase was recently identified as an enzyme that takes charge of 
ghrelin acylation, ghrelin O-acyltransferase (GOAT) [197]. Mouse genome 
results demonstrated that GOAT belongs to a family of 16 hydrophobic 
membrane-bound acyltransferases. This transferase includes porcupine (attaches 
to Wnt proteins) [198]. GOAT mRNA has a negative relationship with ghrelin in 
the major ghrelin-secreting tissues. Additionally, a novel 23-amino acid peptide 
was recently identified from rat stomach, called obestatin [199]. Obestatin is 
expressed from the mammalian preproghrelin gene. Several authors reported 
that the ghrelin gene products, such as acyl ghrelin, des-acyl ghrelin and 
obestatin, are all related to distinct feeding behaviours, and delicately coordinate 
digestive processes and regulation of energy balance [200-203].  
1.6.3 Mechanisms of action 
Ghrelin directly connects to and activates growth hormone secretagogue 
receptor (GHSR) to enhance GH release. The post-translational modification of 
octanoylation appears to be critical for the progress of GH release [204]. In 
general terms, AG controls food intake, adiposity, and insulin secretion. By 
means of orexigenic neural circuits, ghrelin regulates systemic metabolism and 
stimulation of gut motility subsequently [192] (Figure 4). DAG has been less 
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reported, but also contributes to the stress response and may have an opposite 
role in regulation hypothalamic circuitry [205]. In animal models, the signals of 
serum AG related to food intake via the hypothalamus and then through the 
gastric vagal afferent pathway [203]. In vivo, signal transduction pathways 
should act via the nucleus of the solitary tract in the brainstem [206]. The nucleus 
of the solitary tract is connected to hunger signalling mediated by insulin [202]. 
Electro-physiologic studies indicate that AG suppresses firing of gastric afferent 
nerves [207]. Taken together, these findings are evidence for the concept that the 
ghrelin system is necessary for the central control of feeding behaviour via a 
ghrelin-associated orexigenic signalling cascade. 
 
Figure 4. Ghrelin, which is mainly secreted by the stomach, affects various systems, including 
the central nervous system (ghrelin activates the GHSR and promotes growth hormone release), 
the immune system, and the cardiovascular system. AG controls food intake, increases 
pro-inflammatory factors, glucose and lipid metabolism, and promotes gastrointestinal motor 
function and cellular proliferation [208]. It may be speculated, that abnormal ghrelin-associated 
metabolism may contribute to the development of LUTS suggestive to BPH [94]. CNS: central 
nervous system, BBB: blood-brain barrier. (Diagram materials from 
https://www.vectorstock.com/) 
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1.6.5 Major functions  
Of the functions of ghrelin, energy balance should be mentioned first. In the 
early 21
th 
century, human studies have targeted the altered serum ghrelin 
expression in abnormally thin and obese subjects (based on BMI) [209]. For 
instance, AG level influence the endogenous circulating hormone levels in the 
process of insulin resistance and obesity [205]. Previous studies suggested that 
AG enhances proliferation of different cell types [210-212]. Interestingly, the 
role of DAG remained initially unclear, but it was recently reported that it 
inhibits the apoptosis of pancreatic beta-cells [213, 214]. The function of DAG 
on food intake is more complex and remains unclear. In fact, previous studies 
presented opposite results of the effect of DAG on proliferation in different types 
of cells [190, 215, 216]. Taken together, published data on functions of AG and 
DAG are conflicting. There are evidences suggested that AG and DAG have 
similar effects on food taken, meanwhile also opposite effects in other biological 
functions [217]. Recent findings suggested that the balance of the AG/DAG ratio 
may regulate insulin actions in the metabolic syndrome. The unbalanced 
AG/DAG ratio may contribute to the insulin resistance and increases body mass, 
and induces metabolic stress and abnormal hormone level in plasma 
subsequently [217].  
 
Generally, serum ghrelin levels were much higher in patients with anorexia 
nervosa than in healthy subjects, and increasing weight reduced serum ghrelin to 
normal levels in these patients [216]. Researchers believe that the possible 
reason may be the loss of sensitivity or resistance to ghrelin expression in human 
serum. On the other hand, the ghrelin level, in cortical tissue, may be 
overexpressed in patients who are suffering with anorexia nervosa [218]. 
Ghrelin produces a significant rise in human plasma glucose levels, which are 
according to a decrease in insulin release [210, 219]. The explanation of this 
phenomenon has been debated for a long time. C. Gauna et al. suggested that the 
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administration of unacylated human ghrelin might lead to insulin sensitivity 
[220]. 
 
Ghrelin enriched T cells in elderly humans and animal models [221]. Meanwhile, 
the thymus involuted and T-cell production declined. Nevertheless, in an animal 
model, the long-term management of ghrelin increased GH/insulin-like growth 
factor I levels and stimulated growth and cell differentiation, meanwhile, 
increased T-cell proliferation [222]. Ghrelin also regulated the pro-inflammatory 
cytokines release [222]. In animal models, ghrelin decreased endotoxin-induced 
anorexia and cytokine production, while it improved mortality associated with 
lipopolysaccharide (LPS)-induced endotoxin shock [205]. Additionally, Collden 
et al. suggested that ghrelin and the GHSR are found in human T cells and 
monocytes [223]. Furthermore, it is specifically that ghrelin inhibited the chronic 
synthesis of pro-inflammatory anorectic cytokines (for instance, leptin, IL-6, 
interleukin 1ß (IL-1ß), and tumour necrosis factor-1). 
 
Cardiovascular effects of ghrelin are also widely reported, particularly the effect 
of ghrelin on cardiovascular smooth muscle [224]. Various evidence supports a 
functional role for ghrelin in the proliferation of myocardial cells related to 
improved cardiac function [225]. Ghrelin inhibition of apoptosis in 
cardiomyocytes and in endothelial cells via the activation of extracellular 
signal-regulated kinase 1/2 and Akt serine kinases has been widely reported in 
experimental studies [226]. Another important point is that even though 
cardiomyocytes connect to ghrelin with high affinity, they do not express 
GHSR1a, which means that there are other subtypes of ghrelin receptors in the 
cardiovascular system [191].  
 
Ghrelin, a gastrointestinal hormone, exerts its effects by cooperation with 
GHSRs [227]. Increasing evidence has suggested that ghrelin has a wide variety 
of biological functions, one of which is to promote motility of the 
gastrointestinal system [225]. For instance, administration of ghrelin in 
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peripheral organs increase the motility of the gastrointestinal tract. In vitro, 
ghrelin increases the contraction amplitude of the muscle strips, which is a 
dose-dependent process, even though the rhythm is not altered by ghrelin. In 
parallel, ghrelin receptors are widely found in gastrointestinal cell lines [228]. 
Ghrelin has a proliferative effect on Cajal cells, which produce slow waves of 
contraction and connect to adjacent smooth muscle cells to generate spontaneous 
rhythmic contractions [229]. Furthermore, based on histological studies, Cajal 
cells have been connected with adjacent smooth muscle cells of the 
gastrointestinal and urinary tract, which is also a target for ghrelin [230]. 
 
Taken together, the reported functions of ghrelin inspire researchers to explore 
the effect of ghrelin in other systems, such as the respiratory system [192]. The 
distribution of ghrelin receptors in tissues may indicate that they are the target 
tissues for ghrelin [231].  
1.6.6 Role of ghrelin in disease  
Ghrelin has been reported as the only known systemic orexigenic factor; in lean 
patients, serum ghrelin expression fluctuates according to energy intake. 
Alterations in ghrelin secretion appears to influence the fluctuations in serum 
ghrelin associated with different metabolic and disease states. Ghrelin has a 
strong growth hormone (GH)-releasing activity via stimulating of the GHSR1a 
[232]. Importantly, GHSRs are mainly concentrated in the unit of 
hypothalamus-pituitary. Two main functions should be mentioned: achieving 
appetite and regulating energy balance; also, managing pancreatic endocrine 
function and affecting glucose levels. Both play critical roles in the progress of 
obesity [233]. Surprisingly, various studies reported decreased ghrelin levels in 
obese patients [233, 234]. However, they did not distinguish between AG and 
DAG [192]. In fact, the balance of the AG/DAG level is altered in obese patients, 
so that the ghrelin system may contribute to obesity [235]. 
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Additionally , it is potentially beneficial that ghrelin and its receptors reduce 
breakdown of proteins and weight loss in catabolic conditions, including cancer 
cachexia and age-related frailty [236, 237]. Clearly, ghrelin increases food 
intake and body weight in humans [233], and enhances cell proliferation and 
differentiation in different cell lines [223, 237-239]. Specially, in term of 
cardiovascular smooth muscle cells, ghrelin may increase the smooth muscle 
tone [240].  
1.6.7 Summary 
Ghrelin, a metabolism-related hormone, increases food intake in a 
dose-dependent manner, and increases appetite both by enhancing feeding by 
metabolic need and by rewarding feeding behaviour [241]. The latest studies on 
biological roles of ghrelin demonstrated that it could have various physiological 
functions. Ghrelin has potential GH-releasing, orexigenic activities, and critical 
effects on the cardiovascular and gastrointestinal systems [217].  
 
Furthermore, ghrelin participates in inflammation and age-associated obesity    
[242]. The ghrelin signaling pathway is an important factor for prostate 
inflammation, which may induce the development of BPH and prostate cancer        
[243, 244]. Metabolic syndrome induces hormone alterations including 
unbalanced AG/DAG ratio, which increases metabolic stress [235]. Moreover, 
this metabolic stress enhances the development of BPH [245]. Together, a 
possible role of the ghrelin system as a molecular link connecting BPH with 
metabolic syndrome appears feasible. In fact, metabolic syndrome is a sustained 
disorder affecting levels of different metabolic hormones, which may involve or 
affect the ghrelin system [93]. 
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1.7 Possible role of the ghrelin system in links between 
metabolic syndrome and LUTS suggestive to BPH  
1.7.1 The relationship between the metabolic syndrome and 
BPH/LUTS 
The relationship between metabolic syndrome and BPH/LUTS has been derived 
mostly from a series of cutting-edge epidemiologic studies [93]. Several 
components of metabolic syndrome, including obesity, glucose intolerance, 
dyslipidaemia, and hypertension, were identified as risk factors for BPH [246]. 
New studies on the development of BPH and BOO support the suggestion that 
metabolic syndrome can affect the natural course of these conditions [23]. 
Although this context has been unequivocally proven by clinical and 
epidemiological observations, the underlying molecular mechanisms are still 
widely unknown. 
 
Adipokines, including ghrelin or other metabolic hormones, play a central role in 
the pathophysiology of metabolic syndrome [247]. However, they have not been 
considered as possible mediators linking BPH/LUTS with metabolic syndrome 
to date [248]. Previous studies addressing molecular mechanisms connecting 
BPH with metabolic syndrome focused on inflammatory mediators and 
lipoproteins [249]. Because ghrelin may increase smooth muscle contractility 
and promotes proliferation in several organs and cell types, a similar role in the 
prostate and for BPH/LUTS may be assumed, besides its role in metabolic 
syndrome. 
1.7.2 Ghrelin system in regulation of smooth muscle tone 
Considering the effect of enhancing smooth muscle contraction, ghrelin has a 
potential in different systems, including the cardiovascular and gastrointestinal 
systems [248]. In vascular smooth muscle, the modulation of contraction and 
arterial pressure control are related to the activities of ghrelin and receptors [250]. 
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In vessels, saphenous vein, internal mammary artery and coronary artery, ghrelin 
receptors were widely detected [251]. Interestingly, ghrelin was widely 
represented on the surface of vascular smooth muscle [252].  
 
Additionally, the ghrelin system was also been reported to influence the 
gastrointestinal system. Ghelardoni et al. found ghrelin mRNA and protein in the 
stomach and almost every section of the small intestine [253]. The mRNA level 
was maximal in the stomach; however, its protein level was quite below that 
measured in the lung. Thus, in the gut, ghrelin protein expression is dissociated 
from mRNA expression [192]. In isolated rat stomach smooth muscle strips, 
ghrelin enhanced the small cholinergic-mediated contraction, stimulated during 
electric field stimulation (EFS) [254].  
 
In terms of the effect of ghrelin on smooth muscle contraction, Fang et al. 
suggested the ghrelin system may be a protective factor on vascular smooth 
muscle cells, and inhibits the increase in the calcium concentration of rat aorta 
vascular smooth muscle cells (VSMCs) [240]. Dimitrova et al. reported that, in 
human mesenteric arteries, the ghrelin system increased the force of contraction 
via Src kinase and mitogen-activated protein kinase (MEK) [255]. Using an 
animal model, Mladenov et al. suggested that ghrelin increased the tension of 
endothelin-1 induced contraction in pig femoral arteries [256]. According to 
previous studies, in the cardiovascular system, and also in the gastrointestinal 
system, ghrelin appears to promote smooth muscle contraction.  
 
However, the effect of ghrelin and its receptors in human prostatic smooth 
muscle still need to be explored. A possible influence of the ghrelin system in 
LUTS suggestive of BPH appears possible and interesting, as prostate smooth 
muscle contraction is involved in LUTS and an important target for its medical 
therapy.  
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1.7.3 Ghrelin system plays a role in proliferation 
Considering the cellular proliferation, a study on VSMCs, Liang et al. reported 
that the ghrelin system may inhibit the differentiation of VSMCs [257]. 
Moreover, Rossi et al. suggested that ghrelin  inhibits angiotensin II-induced 
proliferation and contraction by means of the cAMP-protein kinase A pathway 
[257, 258]. Accordingly, they suggested that, in terms of vascular damage and 
remodelling, the ghrelin system is a potential therapeutic target. 
 
In contrast, during cardiac remodelling, the effect of ghrelin remains unclear. 
Recently, a study suggested that ghrelin activates the 
Raf-1-MEK1/2-ERK1/2-BAD signalling pathway in the rat model due to its 
anti-apoptotic effect; at the same time, it inhibits cardiac fibrosis [225, 259]. 
Furthermore, in long-term ghrelin treatment, as reported by Yuan et al., vascular 
endothelial growth factor (VEGF) expression increased in the peri-infarct zone 
in myocardial infarction rats compared with a control group, suggesting that 
ghrelin could be a protective factor and improves angiogenesis [260]. 
 
However, to the best of my knowledge, there are no studies concerning 
ghrelin-induced proliferation in non-malignant prostate cells or in prostate 
smooth muscle contraction, but effects on prostate enlargement appear possible. 
1.7.4. Ghrelin system in BPH? 
Very limited studies are available on the role of ghrelin in BPH. However, a 
recently study suggested that significant positive correlation between serum 
PSA and total ghrelin in non-diabetic individuals with BPH, which provide an 
evidence that ghrelin may have a diagnostic role in BPH [261].  
 
Because the ghrelin system may increase smooth muscle contractility and 
promotes proliferation in several organs and cell types, a similar role in the 
prostate and LUTS suggestive to BPH may be considered, within their role for 
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the metabolic syndrome. Taken together, studies about the effect of ghrelin 
system on LUTS suggestive to BPH are assumed to start from two aspects: the 
effect on contraction of prostate smooth muscle and the effect on the 
proliferation of prostate cells. 
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2. Aims 
Current medical therapy of LUTS suggestive to BPH is still influenced by 
insufficient efficacy and low adherence to medications of patients [262]. 
Although pharmacotherapy in BPH has been reported as successful and essential, 
daily practice suggested that there are still inherent limitations. For instance, 
α1-blockers improve the symptom scores no more than 50 % [181]. Recent study 
suggested that the drug adherence rate to α1-blockers was acclaimed lower than 
30 % after starting of the 12 months treatment [263]. 
 
Therefore, it is vital to find more effective options for treatment of LUTS 
suggestive of BPH. An all-round or single-compound medication for treatment 
of voiding symptoms would be optimal. In recent years, the possible linkage 
between contraction of smooth muscle and proliferation of prostatic cells has 
been researched, however, the one-pack solution of LUTS suggestive to BPH is 
still on the way.  
 
Consequently, the aim of this study was to explore the possible role of the 
ghrelin system for proliferation of prostate stromal cells and for contraction of 
prostate smooth muscle. 
 
Specifically, the following questions were subject of in this thesis: 
1. Does a ghrelin agonist increase the viability of a prostatic stromal cell line? 
2. Does a ghrelin agonist increase the proliferation of a prostatic stromal cell 
line?  
3. Does a ghrelin agonist affect the cell cycle of a prostatic stromal cells? 
4. Does a ghrelin agonist affect growth factor mRNA expression? 
5. Does an inverse ghrelin agonist affect contractions of human prostate 
tissues? 
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3. Materials and methods 
3.1 Reagents and devices 
MK-0677 is a non-peptide, small molecular GHSR agonist, which has a higher 
affinity to the GHSR compared to ghrelin [264]. Stock solutions (10 mM) were 
prepared with dimethyl sulfoxide (DMSO), and kept at -20 °C until use. 
Aqueous stock solutions of noradrenaline (10 mM) were freshly prepared before 
each experiment.  
 
PF-5190457, a member of a spiro-azetidino-piperidine series, was identified by 
Pfizer Pharmaceuticals by means of high-throughput screen method [265], 
which is potent and high selective GHSR inverse agonist that enhances 
glucose-stimulated insulin secretion (GSIS) [266]. Stock solutions (10 mM) 
were prepared with DMSO and kept at -20 °C until use. 
Table 1. Reagents used in this study. 
Products Provider 
Dimethyl sulfoxide (DMSO) Roth, Germany 
RPMI 1640 Gibco, USA 
10 % fetal calf serum (FCS) Gibco, USA 
Phosphate-buffered saline (PBS) Gibco, USA 
Sulforhodamine B (SRB) Gibco, USA 
4’, 6’-diamidino-2-phenylindole- 
dihydrochloride (DAPI) 
Invitrogen, USA 
 
Magnesium chloride (MgCl2) Promega, USA  
Reverse transcription buffer 10× Promega, USA 
dNTP Mix Promega, USA 
Random primers Promega, USA 
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Custodiol Köhler, Germany 
Glucose Sigma-Aldrich, Germany 
Carbogen Linde Gas, Germany 
MK-0677 Tocris Bioscience, UK 
PF-5190457 Tocris Bioscience, UK 
Noradrenaline Sigma-Aldrich, Germany 
AMV reverse transcriptase Promega, USA 
Ribonuclease (RNase) inhibitor Promega, USA 
RNase Free Water Promega, USA 
SYBR™ Green Roche, USA 
RT
2
 qPCR Primer QIAGEN, Germany 
RNase Away Thermo Fisher Scientific, USA 
AllPrep DNA/RNA/Protein Mini Kit QIAGEN, Germany 
5-Ethynyl-deoxyuridine (5-EdU) Thermo Fisher Scientific, USA 
Potassium chloride (KCl) Roth, Germany 
Sodium chloride (NaCl) Roth, Germany 
Calcium chloride dihydrate (CaCl2·2H2O) Roth, Germany 
Magnesium sulfate heptahydrate 
(MgSO4·7H2O) 
Roth, Germany 
Sodium bicarbonate (NaHCO3) Roth, Germany 
Potassium dihydrogen phosphate (KH2PO4) 
10x Reaction Buffer with MgCl2  
Roth, Germany 
Thermo Fisher Scientific, USA 
Triton X-100 Thermo Fisher Scientific, USA 
Mounting solution Thermo Fisher Scientific, USA 
Dithiothreitol (DTT) Sigma-Aldrich, Germany 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, Germany 
Propidium iodide Abcam, London, GB 
RNase  Abcam, London, GB 
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Table 2: Devices used in this study. 
Products Provider 
Tissue Bath System-720MO 
 
Electrical Field Stimulation  
 
Lab pump 
DMT (Danish Myotechnology), 
Denmark 
DMT,  
Denmark 
KNF- Neuberger, USA 
Thermostat Memmert, Germany 
Fluorescence Activated Cell Sorter 
(FACS)  
Becton-Dickinson, USA 
Light Cycler PCR system Roche, Switzerland 
Superfrost
®
 microscope slides Thermo Fisher, USA 
Laser scanning microscope Leica SP2, Germany 
Lab-Tek chamber slides Thermo Fisher, USA 
Cell culture incubator Thermo Fisher, USA 
Waterbath Thermo Fisher, USA 
Centrifuge Thermo Fisher, USA 
Nanodrop
TM
 Thermo Fisher, USA 
 
3.2 Human prostate tissues 
Human prostate tissues were obtained from patients undergoing radical 
prostatectomy for prostate cancer (n = 19). All prostates were transported in 
Custodiol
®
 (Köhler, Germany) to the Department of Pathology immediately 
(less than 1 hour) after prostatectomy and then directly macroscopically 
examined by pathologists. Tissue samples were then obtained from the 
periurethral zone, where no tumors were observed. Patients were not included, if 
they were received transurethral resection of prostate (TURP) or brachytherapy 
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before radical prostatectomy. If any prostatic stones, or fibrotic parts were 
observed, these tissues were also excluded. 
 
The research was carried out according to the Declaration of Helsinki of the 
World Medical Association, and has been approved by the ethics committee of 
the Ludwig-Maximillians University, Munich, Germany. Human prostate 
tissues were stored in Custodiol
®
 at 4 °C for organ bath studies for a maximum 
of 90 min.  
3.3 Cell culture 
WPMY-1 cells (human prostate stromal cell line) used in this study were 
purchased from the American Type Culture Collection (ATCC Manassas, VA, 
USA). WPMY-1 is an immortalized cell line from human prostate stroma, 
without malignant transformation [267]. Cells were cultured in Roswell Park 
Memorial Institute (RPMI)1640 (Gibco, Carlsbad, CA, USA) supplemented 
with 10 % fetal bovine serum (FCS) (Gibco, Carlsbad, CA, USA) and 1 % 
penicillin (Gibco, Carlsbad, CA, USA) and streptomycin (Gibco, Carlsbad, CA, 
USA) at 37 °C in a humidified atmosphere with 5 % CO2.  
3.4 Real time polymerase chain reaction (RT-PCR) 
RNA isolation from cells was performed using the RNeasy Mini kit (Qiagen, 
Hilden, Germany). RNA concentrations were measured spectrophotometrically. 
Reverse transcription to cDNA was performed with 1µg of isolated RNA using 
the Reverse Transcription System (Promega, Madison, MI, USA). RT-PCR for 
Ki-67, IGF-1, EGF, FGF-2, TGF-β1, cyclin D1, CDK2, CDK4, E2F3 and actin 
was performed with a Roche Light Cycle (Roche, Basel, Switzerland) using 
primers provided by Qiagen (Qiagen, Hilden, Germany) as ready-to-use mixes. 
PCR reactions were performed in a volume of 25 µL. Denaturation was 
performed at specific temperature ranges. The specificity of primers and 
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amplification was demonstrated by subsequent analysis of melting points, which 
revealed single peaks for each target. Results were expressed using the ΔΔCP 
method, where number of cycles (Ct) at which the fluorescence signal exceeded 
a defined threshold for actin was subtracted from Ct values for targets, and 
values were calculated as ΔΔCP and normalized to each other. 
3.4.1 Reverse Transcription (RT) 
RNA samples were incubated at 70 °C for 10 min. Thereafter, 1 µg of RNA 
sample was reversing transcribed using Reverse Transcription System (Promega, 
Madison, WI, USA) (Table 3). 
Table 3: Reverse Transcription  
Components Volumes (µL) 
Random hexamer oligodeoxyribonucleotides  0.5 
Ribonuclease inhibitor  0.5 
Reverse-transcriptase   0.65 
dNTP mix 2 
10xRT buffer 2 
MgCl2 4 
RNase-free water 10.35 
3.4.2 Primers 
All primers (Table 4) were provided by Qiagen (Hilden, Germany) as 
ready-to-use mixes (www.qiagen.com). All primers were stored at -20 ℃ . 
Table 4: Primers  
Primer full name RefSeq accession number 
Marker of proliferation Ki-67  
(Ki-67) 
NC_000010.1 
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Cyclin-dependent kinase 2 (CDK2) NM_001798 
Cyclin-dependent kinase 4 (CDK4) NM_000075.4 
Insulin-like growth factor 1  
(IGF-1) 
NM_198541 
Epidermal growth factor (EGF) NM_00118130 
Fibroblast growth factor 2 (FGF-2) NM_031950 
Tranforming growth factor β1 (TGF-β1) NM_001142621 
E2F transcriptin factor 3 NM_001949 
RefSeq represent reference sequence from national center for biotechnology 
information (NCBI). 
3.4.3 Real-time polymerase chain reaction (RT-PCR) 
RT-PCR for proliferation markers, including Ki67, CDK2 and CDK4, growth 
factors, including IGF-1, EGF, TGF, FGF, and cell cycle regulating factor E2F3 
and actin was performed with a Roche Light Cycler (Roche, Basel, Switzerland). 
PCR reactions were carried out in a volume of 25 µL, which contained 5 µL 
Light Cycler® FastStart DNA Master Plus SYBR Green I (Roche, Basel, 
Switzerland), 1 µL template, 1 µL primer, and 18 µL water. The settings run on 
the Light Cycler were used as followed. 
 
Denaturation was performed for 10 min at 95 ℃ , and amplification with 45 
cycles of 15sec at 95 ℃  followed by 60 sec at 60 ℃ . The specificity of primers 
and amplification was demonstrated by subsequent analysis of melting points, 
which revealed single peaks for each target. ∆∆CP crossing points (CP) method 
was used to express the results [268]. 
3.5 Cell proliferation assay 
WPMY-1 cells were plated with a density of 50,000/well on a 16-well 
chambered coverslip (Thermo Scientific, Waltham, MA, USA). After 24 hours, 
cells were treated with MK-0677, or DMSO. After further 24 hours, the medium 
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was changed to a 10 mM 5-ethynyl-2’-deoxyuridine (EdU) solution in FCS-free 
medium containing agonist or solvent (DMSO). 20 hours later, cells were fixed 
with 3.7 % formaldehyde. EdU incorporation was determined using the 
“EdU-Click 555” cell proliferation assay (Baseclick, Tutzing, Germany) 
according to the manufacturer`s instructions. This method is a method for 
labeling DNA in vivo that allows to depict the replicate DNA in the context of 
well preserved cellular and chromatin ultrastructure. EdU is readily incorporated 
into cellular DNA during DNA replication. 
 
In this assay, incorporation of EdU into DNA is assessed by detection with 
fluorescing 5-carboxytetramethylrhodamine (5-TAMRA). Counterstaining of 
all nuclei was performed with DAPI.  Experiments were performed using the 
following protocol: 
1. Cells were cultured on the glass coverslips in the RPMI medium with 10 % 
serum for 24 hours. 
2. After the attachment of the WPMY-1 cell, the medium was replaced by 
serum free medium containing 5 % EdU. 
3. Cells were exposed to MK-0677 or DMSO for 24 hours. 
4. Medium was removed followed by washing the plates with PBS two times.  
5. Cells on the plate were fixed with formaldehyde. Residual EdU medium 
mixture was removed and 90 µL paraffin was added in each well, followed 
by waiting for at least 15 min at room temperature before washing. 
6. BSA/PBS solution was prepared in the plastic holder. Paraffin was removed 
from the plates and washed by 95 µL BSA/PBS solution two times. 
7. Plates with cells were treated with 90 µL vortexed triton and incubated at 
room temperature for 20 min. Thereafter, 30 µL of EdU cocktail mixture was 
added in each well.  
8. Residue was removed and covered with glass.  
9. A laser scanning microscope (Leica SP2, Wetzlar, Germany) was applied to 
analysis the labeled cells. 
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3.6 Plate colony formation test 
Cells were incubated at 37 °C for 14 days, then washed twice with 
phosphate-buffered saline, and fixed by 2 mL 10 % trichloroacetic acid (TCA) 
4 °C overnight. After that, all plates were washed with cold water five times, and 
stained with 0.4 % Sulforhodamine B (SRB) solution (diluted in 1 % acetic acid) 
at room temperature for 30 minutes. Before analysis, all plates were labeled and 
washed by 1 % acetic acid five times. The number of colonies containing 50 cells 
or more was counted under a microscope. Experiments were performed using the 
following protocol: 
1. 100 cells were seeded in each well in 6 well plates. Final confluence of 70 % 
growth area in one well of 6 well plate provides satisfactory results according 
to previous experimental results. 
2. MK-0677 was applied to cells in different concentration. DMSO was applied 
to control group. 
3. Cells were stained with SRB after 14 days. 
4. Plates were washed by PBS two times.  
5. 10 % TCA solution (250 µL to 1 mL per well) was added for fixation, which 
could totally cover the whole surface area of the plate. 
6. Cells were incubated in 4 °C for at least 1 hour. 
7. TCA solution was removed from the plates, and plates were dried in room 
temperature. 
8. 1 mL SRB reagent (contain 1 % acetic acid) per well was added, followed by 
30 min incubation at room temperature. 
9. All plates were washed with 1 % acetic acid, and plates were dried in room 
temperature. 
10. All plates were recorded and analyzed by ImageJ (NIH, Maryland, USA). 
Based on the equation as following, the formation efficiency could be 
obtained. The formation efficiency could represent the long-term 
proliferation ratio. 
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Plate colony formation efficiency =           ×100 % 
 
3.7 Cell cycle analysis 
Cells were fixed with ethanol and centrifuged at 500 g for 5 min.The ethanol 
supernatant was discarded and cells were suspended in 1 mL of pre-cooled 
phosphate-buffered saline (PBS) for 1min, and then centrifuged at 500 g for 5 
min. The cells were suspended in 200 µL propidium iodide (PI) and RNase 
staining mixture solution. After incubation in the dark at 37 °C for 30 min, cells 
were sorted on a fluorescence-activated cell sorting (FACS) flow cytometer (BD 
Biosciences, Franklin Lakes, NJ, USA). For setting the flow cytometer, the 
excitation should be regulated at 488 nm for generating DNA distribution 
histograms.  
 
Based on setting, 10,000 events were analyzed for each sample using ModFit LT 
software (Verity Software House, Torpsham, ME, USA). Experiments were 
performed using the following protocol: 
1. PI and RNase solution were prepared as follow: 
1 x PBS 9.45 mL 
20 x PI (1 mg/mL) 500 µL 
200 x RNase (110,000 U/mL) 50 µL 
PI and RNase Solution 10 mL 
2. 200,000 cells each well in 6 well plates were seeded for this examination. 
3. Medium was removed after the cell attachment, and cells were washed with 
PBS and trypsin in order to dispatch the cells from the flasks.  
4. Once the cells were fully trypsinized, the cells were pelleted at 500 g for 5 
min and the supernatant was discarded. 
5. Cells were washed twice by PBS and centrifuged again, before fixation of all 
cells. 
Number of colonies 
Number of cells seeded 
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6. Cell pellet was gently suspended in 400 µL cold PBS. 800 µL ice cold 100 % 
ethanol was added into each well. Plates with cells were stored at 4 °C for at 
least 2 hours. After that, the prepared sample from 4 °C were transferred to 
the bench and equilibrate to room temperature. 
7. Cells were treated with the PI and RNase solution on the cell samples, after 
two times cold PBS washing, 
8. Samples were incubated at dark and 37 °C for around 20 min. 
9. Samples were placed on ice and subjected to the FACS analysis. 
10. Before the samples undergo the FACS analysis, the setting and 
tranquilization should be finished. 
11. Appropriate (forward scatter) FSC vs. (side scatter) SSC gate were 
established to cell debris and cell aggregates. 
12. Data were collected in FL2 (channel 2) via 488 nm laser illumination. 
13. Markers were setted up on a histogram plot to discribe such like , < 2N, 2N, 
2N-4N(DNA synthesis), 4N and > 4N intensity regions facilitates 
quantifying differences in DNA content between different samples. Expect to 
see a two-fold intensity different between 2N (G1 stage) and 4N (mitotic) PI 
peaks. 
3.8 Viability assay 
Viability of WPMY-1 cells was assessed using the cell counting kit (CCK-8) 
(Sigma Aldrich, Munich, Germany) according to the instruction provided by 
manufacturer. CCK-8 allows WST-8 
(2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetra
zolium, monosodium salt) to penetrate living cells, inducing formazan dye. This 
colorimetric assay reflects cell viability. Experiments were performed using the 
following protocol: 
1. Cell suspension (20,000 cells per well) was seeded in 96-well plates and 
incubated in a humidified incubator (5 % CO2, 37 °C) for 24 hours.  
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2. Medium was replaced by serum free medium, which could diminish the 
influence of unknown concentration of serum, after cells attached in plates. 
3. MK-0677 was added into each well (final concentrations were 100 nM to 300 
nM). DMSO as control. 
4. Cells were incubated for different time spans: 24 hours, 48 hours or 72 hours. 
5. 10 µL of CCK-8 was added to each well of the plate at the end of each time 
point (24 hours, 48 hours or 72 hours). Separate control experiments were 
performed for each time point. Bubbles to the wells in this procedure were 
avoided. 
6. Cells were incubated for 2 hours, and measured the absorbance at 450 nm in 
microplate reader. 
7. OD-values were collected and analyzed.  
3.9 Tension measurements 
Smooth muscle contractions of human prostate tissue were assessed by 
myographic measurements using an organ bath of the model 720MO (Danish 
Myotechnology, Ahus, Denmark). DMSO for controls, and PF-05190457 were 
added 30 min before contractions were induced by electric field stimulation 
(EFS) or noradrenaline. In each experiment, tissue from the same prostate was 
allocated to all four channels of one organ bath, and DMSO and PF-5190457 
were added to two of the four channels, respectively. For calculation, tensions 
were expressed as % of KCl-induced contraction. Experiments were performed 
using the following protocol: 
1. Krebs Henseleit (KH) solution was prepared before organ bath experiments. 
KH was maintained at 37 °C and continuously bubbled with carbogen (95 % 
O2, 5 % CO2) in a thermostatic container. 
2. Chambers were rinsed with KH solution and filled with 10 mL KH solution, 
before the experiments. 
3. Prostate strips were carefully incised from fresh prostate tissues.  
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4. Once the prostate tissue was secured to the needles, the tissue was mounted 
in the organ bath. 
5. All the tissues were stretched to 4.9 mN and equilibrated for 45 min. During 
this step, spontaneous decreases in tone were usually observed. Therefore, 
tension was adjusted three times during the equilibration period in order to 
obtain a stable resting tone of 4.9 mN. 
6. High molar KCl (final concentration was 80mM) was added to each chamber 
to induce the maximal KCl-induced contraction of prostate strips. 
Subsequently, the chambers were washed with KH solution and refilled with 
KH solution.  
7. PF-5190457 10 μL (10 mM stock solution, final concentration in the organ 
bath chamber was then 10 µM) dissolved in DMSO was added to two 
chambers. 10 µL DMSO was added to other two chambers as control. 
Subsequently, PF-5190457 and DMSO were applied to prostate strips at least 
30 min before adding noradrenaline or applying EFS.  
8. 30 min after adding PF-5190457 and DMSO, frequency-response curves for 
EFS and concentration-response curves for noradrenaline were obtained. 
Frequencies used for EFS in this study were 2 Hz, 4 Hz, 8 Hz, 16 Hz, and 32 
Hz. The cumulative concentrations of noradrenaline were 0.1 µM, 0.3 µM, 1 
µM, 3 µM, 10 µM, 30 µM and 100 µM. 
9. For calculation, tensions were expressed as % of KCl-induced prostate 
smooth muscle contraction.  
3.10 Statistical analysis 
Data in this study are presented as means ± standard error of the mean (S.E.M) 
with the indicated number of each experiment. Both values were calculated 
using GraphPad Prism 6 (Statcon, Witzenhausen, Germany). Multivariate 
analysis of variance (ANOVA) used to calculate unpaired observation, and 
two-way ANOVA were used to calculate paired observations. Both of these 
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calculations were performed with SPSS
®
 20.0 (IBM SPSS Statistics, Armonk, 
New York: IBM Corporation). P values < 0.05 were considered to be statistically 
significant. Cell cycle analysis was measured by the Modfit LT system (Verity 
Software House, Topsham, USA). Cell colony assay was measured by the 
ImageJ (NIH, Maryland, USA). Modfit performs its automatic analysis of the 
sample. It scans the histogram for peaks. Based on the sizes and positions, the 
program attempts to determine the number of cell cycles in the sample. 
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4. Results 
4.1 Effects of MK-0677 on WPMY-1 cells 
4.1.1 Effects of MK-0677 on viability of WPMY-1 cells 
After exposure to 100 nM and 300 nM of MK-0677 for 24 hours, relative OD 
values were 1.14 ± 0.11 and 1.12 ± 0.11, respectively (p < 0.0001 for control vs. 
MK-0677), compared to controls which were normalized to 1. After 48 hours of 
incubation with 100 nM and 300 nM of MK-0677, relative viability was 1.35 ± 
0.23, and 1.24 ± 0.18, respectively (p < 0.0001 for control vs. MK-0677) 
compared to controls which were normalized to 1 (Figure 5).   
 
Figure 5: Effect of MK-0677 on viability of WPMY-1 cells was examined by CCK-8 assay. *p 
< 0.0001 for control vs. MK0-677. Data are shown as means ± S.E.M. from n = 5 independent 
experiments. 
4.1.2 Effects of MK-0677 on proliferation of WPMY-1 cells in EdU 
assay 
In EdU assay, nuclei of proliferating cells are shown in pink, while nuclei of 
non-proliferating cells are shown in blue. The relative number of proliferating 
cells (pink nuclei) was notably higher after treatment with 100 nM of MK-0677 
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(Figure 6), compared with solvent-treated controls. This increase of proliferation 
rate in response to 100 nM MK-0677 occurred after 24 hours of incubation.  
 
 
Figure 6: Proliferation rate assessed by EdU assay after incubation with solvent or MK-0677 
(100 nM and 300 nM) for 24 hours. The number of cells showing proliferation (pink nuclei) 
was referred to the total number of cells (pink + blue nuclei). Shown are representative images 
and means ± S.E.M. from series with n = 5 independent experiments for each setting (* p < 
0.0001 for corresponding control vs. MK-0677 100 nM). 
4.1.3 Effects of MK-0677 on proliferation of WPMY-1 cells in colony 
plate assay 
The initial cell number was 100 per well in the 6 well plates, which widely 
scattered in the whole growth area of every well. After 14 days incubation, 
formation of colony groups were observed, which are stained purple (Figure 7).  
 
The number of stained colonies was counted. In plate colony assay, colony 
formation was increased by MK-0677 (for control vs. MK-0677 100 nM, 
numbers of colonies were 34.8 ± 5.6 and 49.6 ± 9.7, respectively). Colony 
formation was not significantly increased by 300 nM MK-0677, number of 
colonies were 43.8 ± 7.9. 
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Figure 7: Effects of MK-0677 on proliferation of WPMY-1 cells in plate colony assay. 
WPMY-1 cells treated with 100 nM and 300 nM MK-0677 displayed much more and larger 
colonies (*p < 0.02 for MK-0677 100 nM vs. control). Shown are representative experiments 
(upper panel) and means ± S.E.M. from n = 5 independent experiments (lower panel). 
4.1.4 Effects of MK-0677 on cell cycle of WPMY-1 cells  
WPMY-1 cells were incubated with 100 nM MK-0677 for 24 hours (Figure 8 A), 
and cell populations in G1 phase, S phase and G2/M phase were assessed by 
means of flow cytometry. The percentage of cells in G1 phase was 63.4 % ± 
2.44 % and 61.3 % ± 2.45 %, respectively (p = 0.0218, control vs. MK-0677 100 
nM). Cell population in G2/M was 4.19 % ± 1.88 % and 7.21 % ± 1.02 %, 
respectively (p < 0.0001, control vs. MK-0677 100 nM). Histogram shown that 
MK-0677 significantly decreased the cell distribution in G1 phase and increased 
in G2/M phase after 24 hours. 
 
After incubation with 100 nM MK-0677 for 48 hours (Figure 8B), the 
percentage of cell population in G1 was 63.0 % ± 2.97 % and 61.2 % ± 2.27 %, 
respectively p = 0.0654 for control vs. MK-0677 100 nM, meanwhile cell 
population in G2/M was 4.89 % ± 1.65 % and 7.18 % ± 0.95 %, respectively (p < 
0.0001, control vs. MK-0677 100 nM). After 48 hours incubation of MK-0677, 
histogram shown that MK-0677 significantly increased in G2/M phase, but no 
effect on G1 phase. 
  56 
 
 
Figure 8: Effects of MK-0677 on cell cycle in WPMY-1 cells (A for 24 hours and B for 48 
hours), assessed by flow cytometry analysis. Histograms show representative experiments, 
while diagrams show results from quantification of the cell population in the G1, S, and G2/M 
phase (After 24 hours, *p < 0.03 for G1 phase of control vs. MK-0677 100 nM, *p < 0.0001 for 
G2/M phase of control vs. MK-0677 100 nM; after 48 hours, *p < 0.0001 for G2/M phase of 
control vs. MK-0677 100 nM). Shown are means ± S.E.M. from n = 5 independent 
experiments.  
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4.2 Effect of MK-6077 on mRNA profiles of WPMY-1 cells 
4.2.1 Effects of MK0-677 on proliferation markers of WPMY-1 cells 
via RT-PCR  
Expression levels of Ki-67, cyclin D1, and CDK4 in WPMY-1 cells were 
assessed by RT-PCR. Significant higher expression levels of Ki-67, cyclin D1 
and CDK4 were detected in MK-0677 treated cells, compared to solvent-treated 
cells (Figure 9).  
 
Figure 9: Effects of MK-0677 (100 nM, 24 h) on mRNA expression of different proliferation 
markers. Analyses were performed by RT-PCR for Ki-67, cyclin D1 and CDK4. Shown are 
means ± S.E.M. from n = 5 independent experiments for each primer (*p < 0.05 vs. control). 
Relative CT value are ΔΔCP values (2^-(Cttarget-CtGAPDH), which are normalized to the mean of 
the control group. 
4.2.2 Effects of MK-0677 on cell cycle regulating factors mRNA of 
WPMY-1 cells  
In WPMY-1 cells, mRNA of CDK2 and E2F3 were detected by RT-PCR. 
Significant lower expression levels of CKD2 were detected in MK-0677 treated 
cells, compared to solvent-treated cells. In contrast, expression levels of E2F3 
were not changed (Figure 10). 
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Figure 10: Effects of MK-0677 (100 nM, 24 h) on mRNA expression of cell cycle regulating 
factors, including CDK2 and E2F3. Shown are means ± SEM from series with 5 independent 
experiments for each primer (*p < 0.05 vs. control). Shown are means ± S.E.M. from series 
with n = 5 independent experiments for each primer (*p < 0.05 vs. control). Relative CT value 
are ΔΔCP values (2^-(Cttarget-CtGAPDH), which are normalized to the mean of the control group. 
4.2.3 Effects of MK-0677 on growth factors of WPMY-1 cells  
Expression levels of IGF-1, EGF-2, FGF-2 and TGF-β1 in WPMY-1 cells were 
assessed by RT-PCR. In WPMY-1 cells with incubated with 100 nM MK-0677 
for 24 hours, significant higher expression levels of IGF-1 were observed 
compared to solvent-treated cells (Figure 11). However, there was no significant 
difference of expression levels of EGF-2, FGF-2 and TGF-β1 between the 
control and MK-0677 treated groups. 
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Figure 11: Effects of MK-0677 on mRNA expression of growth factors. Analyses were 
performed by RT-PCR for IGF-1, EGF, FGF-2 and TGF-β1 (growth markers). Shown are 
means ± S.E.M. from series with n = 5 independent experiments for each primer (*p < 0.05 vs. 
control. Relative CT value are ΔΔCP values (2^-(Cttarget-CtGAPDH), which are normalized to the 
mean of the control group. 
4.3 Effects of PF-05190457 on human prostate smooth 
muscle contraction  
4.3.1 Effects on EFS-induced contractions 
Frequency-dependent contractions of prostate tissue were induced by means of 
EFS (2-32 Hz). PF-5190457 in a concentration of 10 µM decreased EFS-induced 
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contractions of prostate strips. Multivariate analysis was conducted to compare 
frequency-response curves at different stimulation frequencies (p = 0.008 
compared to DMSO at 32 Hz). Two-way ANOWA was applied to compare the 
difference between DMSO and PF-5190457 groups (p = 0.07 vs. DMSO) 
(Figure 12). 
 
Figure 12: Effects of PF-5190457 on EFS-induced contractions of human prostate tissue. In an 
organ bath, contractions of prostate strips were induced by EFS. Shown are means ± S.E.M. 
from series using tissue from n = 10 patients, with tissues from each patient being allocated to 
the DMSO and the PF-5190457 group (*p < 0.05 for control vs. PF-5190457 in multivariate 
analysis). Contractions were referred to 2 M KCl-induced tension, to correct any heterogeneity 
of tissues and patients. 
4.3.2 Noradrenaline-induced contractions 
Concentration-dependent contractions of prostate tissue were induced by means 
of noradrenaline (0.1-100 µM). Multivariate analysis revealed that inhibition by 
PF-5190457 was significant at 10 and 30 µM of noradrenaline (p < 0.02 vs. 
DMSO). However, the inhibiting effect of PF-0519457 was inverted at 100 µM 
of noradrenaline (p < 0.02 vs. DMSO) (Figure 13). Two-way ANOWA was 
conducted to compare the difference between DMSO and PF-5190457 (p < 
0.001 for PF-5190457 vs. DMSO).  
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Figure 13: Effects of PF-5190457 on noradrenaline-induced contractions of human prostate 
tissue. Shown are means ± S.E.M. from a series using tissues from n = 9 patients, with tissues 
from each patient being allocated to a DMSO and a PF-5190457 group (*p < 0.05 for control vs. 
PF-5190457 in multivariate analysis). Contractions were normalized to 2M KCl-induced 
tension, to correct any heterogeneity of tissues and patients. 
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5. Discussion  
Prostatic cell proliferation and prostate smooth muscle tone are essential for 
etiology and therapy of LUTS suggestive of BPH. Both are responsible for 
urethral obstruction and BOO in prostate enlargement. Currently, α
1
-blockers to 
relax prostate smooth muscle are the first line treatment of male LUTS 
suggestive of BPH. However, it is widely accepted that the efficacy of 
α
1
-blockers is limited [119]. In order to overcome the limitation of current 
treatments in BPH, novel therapies should be considered. 
 
Metabolic factors should be taken into account in the treatment of LUTS 
suggestive to BPH. The present study may suggest that metabolic hormones 
promote growth in the hyperplastic prostate, which may initiate development of 
BPH and LUTS suggestive of BPH in patients with metabolic syndrome [21]. 
 
According to the results in another thesis of the lab, where this thesis was 
performed, ghrelin agonists increase prostate smooth muscle tone in 
α1-adrenergic and neurogenic contraction. The present thesis suggests that 
ghrelin agonists may also increase the proliferation of prostate stromal cells. 
Here, an inverse GHSR agonist inhibited the α1-adrenergic and neurogenic 
prostate smooth muscle contraction. Together, this supports the idea that the 
ghrelin system may take part in the development of LUTS suggestive of BPH. 
Inhibiting the activities of the ghrelin system could bring novel options for the 
treatment of LUTS suggestive to BPH. The ghrelin system may be a molecular 
mechanism connecting the development of BPH/LUTS with the metabolic 
syndrome. Such a relationship emerged clearly from previous epidemiologic 
studies, while underlying molecular mechanisms are still widely unclear. 
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5.1 Ghrelin and GHSR take part in proliferation and 
contraction in different systems 
GHSR is a member of the G protein-coupled receptor family, and regulates 
growth hormone secretion. Expression of GHSR in adults is  found in different 
regions, including the stomach, the central nervous system (CNS), pituitary 
gland, vascular endothelium and other peripheral tissues [269]. Ghrelin 
specifically binds to the GHSR with high affinity, and produces a complex 
compound of ghrelin-GHSR which is associated with internalization [188]. 
Based on neurological studies, activation of GHSR is critical for proliferation 
and migration of glioma cells [270]. Furthermore, emerging evidence suggested 
that GHSR activation enhances the proliferation of airway and gastrointestinal 
smooth muscle cells [271]. Ghrelin-enhanced proliferation and cell growth have 
been reported for different cell types [190, 222, 272, 273]. In a study using rat 
hippocampal neural stem cells (NSCs), ghrelin stimulated the cellular 
proliferation by means of accelerating progression of cell cycle phase from G1 to 
G2/M [274]. Wang et al. suggested that ghrelin improved proliferation of 
hepatocytes by regulating cell cycle via GSK3β/ catenin signaling pathway [200]. 
In detail, exposure of ghrelin leads to a shift from G1 phase to S phase in the case 
of hepatocytes, which means ghrelin could be a protective factor for patients 
who have liver injury. Thus, ghrelin is a mitotic signal from stomach, but effect 
on other target organs [275]. 
 
Additionally, ghrelin and its receptor were reported to effect on regulation of 
contraction, pressure control and cell proliferation in vascular smooth muscle 
[276]. For instance, ghrelin has an acute effect on relaxation of human artery via 
regulating vascular K
+
 channels [277]. In terms of gastrointestinal smooth 
muscles, ghrelin has an important function on the prokinetic activities in the 
stomach, and increased the intestinal transit [278]. Based on animal experiments, 
ghrelin was reported to accelerate gastric emptying, and improve inter-digestive 
motility [279, 280]. However, there are conflicting reports on ghrelin effects on 
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cells. Rossi et al. suggested that ghrelin inhibits the proliferation of aortic smooth 
muscle cells [258]. Antiproliferative effects were reported on thyroid and breast 
cells [281, 282]. 
 
On the other hand, ghrelin and GHSR were reported to be involved in regulating 
smooth muscle contraction in different cell types. For instance, it has been 
suggested that ghrelin management maintains the spontaneous gastric 
contractions in rat model [283]. Using an in vitro experimental approach, the role 
of ghrelin and GHSR on airway smooth muscle contractions has been observed. 
Ghrelin and GHSR show a potential effect on airway smooth muscle contraction 
via NO signaling [284]. 
 
According to preliminary studies (preceding this thesis) on the human prostate 
tissue and prostatic stromal cells, GHSR mRNA is obviously expressed in both. 
The ghrelin system was assumed to play a role in the development of LUTS 
suggestive to BPH. In order to clarify whether ghrelin takes part in the 
proliferation of prostate cells, the ghrelin agonist MK-0677 was applied here in a 
prostate cell culture model. In terms of prostate smooth muscle contraction, the 
inverse agonist PF-5190457 was applied on prostate tissue.  
5.2 MK-0677 enhances the proliferation of prostate cells and 
regulates their cell cycle. 
MK-0677, which is a selective agonist of the ghrelin receptor, was developed as 
an orally available GHSR ligand [264, 285]. The compounds resulted from 
optimization of preceding lead compounds/precursors to induce growth 
hormone release in rat pituitary cell assays, where MK-0677 showed an EC50 of 
1.3 nM [286]. Oral availability was first confirmed in dog models reference. 32 
beagle dogs were treated with MK-0677 1.0 mg/kg oral administration for 14 
days and the results suggested that MK-0677 can elevate serum IGF-1 levels 
[287]. MK-0677 may activate GHSR-coupled pathways and induces 
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GHSR-mediated effects with EC50 values in the nanomolar range (0.2-1.4 nM) 
[288]. MK-0677 was identified as a competitive receptor agonist [289]. In vitro, 
Lee et al. suggested that oral administration MK-0677 (4 mg/kg) in rats 
increased serum GH (1.8 times higher compared to basal levels), suggesting that 
oral administration of MK-0677 plays a role in the progression of GH-release 
[290].  
 
Meanwhile, clinical trials about MK-0677 exist. In 1999, Murphy et al. 
published a clinical trial on MK-0677 in osteoblasts treatment in elderly patients 
[291]. The results suggested that GH and MK-677 have a stimulatory effect on 
bone remodeling. Adunsky et al. launched a phase II placebo-controlled clinical 
trial of MK-0677 provided novel solution to patients suffering from the hip 
fracture and going through the functional recovery therapy [292]. 
 
MK-0677-induced proliferation of WPMY-1 cells shown in this thesis suggests 
that the ghrelin system takes part in the growth of prostate cells, which was 
confirmed by different readouts, including EdU assay, CCK-8 and plate colony 
assay. Based on the data from flow cytometry, the connection between cell cycle 
regulation and ghrelin dependent proliferation has been demonstrated. By 
activating cyclin-CDK-dependent transcription, prostate stromal cells commit to 
enter a new cell cycle during G1, which might be a potential mechanism of 
ghrelin enhanced prostate cell proliferation.  
 
The increased population of cells in the G2/M phase suggested that cell cycle has 
been accelerated by MK-0677 and over load fracture of G2/M cells were 
detected [293]. Combined with the other readouts including CCK-8 assay and 
EdU assay, the results depict that WPMY-1 cell number and viability are both 
increased after exposure to ghrelin agonists. According to the flow cytometry 
results, MK-0677 significantly increased the cell fracture in G2/M phase, but not 
in the G1 phase, so that the sensible explanation is that cell cycle has been 
accelerated, especially in G1 phase [294]. Taken together, ghrelin agonists may 
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promote the progression of cell cycle, and increase the proliferation of prostate 
cells. 
5.3 MK-0677 alters the profile of cell cycle regulators and 
growth factors  
After exposure to MK-0677, an increased expression of CDK4, and decreased 
expression of CDK2 were observed. Based on studies of separate animal models, 
CDK2/CDK4 play a role in cell cycle regulation and subsequently affect the 
proliferation in different types of cells [295]. For WMPY-1 cells, the current 
results may suggest that ghrelin arrests prostate stromal cells in the G2/M phase 
by regulating CDKs and cyclin [296]. Cyclins and CDKs are cooperating with 
each other in cell cycle. Additionally, CDKs has no function in the absence of a 
cyclin partner. Once activated by a cyclin partner, CDKs coordinate the entry 
into the next phase of the cell cycle [297]. This progression is controlled by 
means of a complicated signaling network. The CDKs, including CDK2 and 
CDK4 are major regulators of cell cycle progression [298] (Figure 14). Taken 
together, MK-0677 may regulate the cell cycle via CDK2/CDK4 in prostate 
cells. 
 
Especially, CDK4 regulates the transfer of cells in the G1 phase into the S phase, 
and cooperates with other functional cytokines, immunoglobulin (IG) 
superfamily, and growth factors. Activity of CDK4 would regulate the function 
of E2F [299]. Subsequently, when the cell cycle into the S phase, E2F stimulates 
the following transcriptional activation of genes that control the rate of 
proliferation in prostate cells [296]. 
 
A main finding of this thesis is, that treatment with a ghrelin agonist increases 
the proliferation rate in prostate stromal cells. In BPH, the prostate enlargement 
may contribute to the symptoms associated to bladder emptying. Taken together, 
  67 
ghrelin agonists may promote prostate cell proliferation by regulation of cell 
cycle and its regulators.  
 
Figure 14: Typically, in a rapidly proliferating human cell line with a total cycle time of 24 
hours, the G1 phase (11 hours), S phase (8 hours), G2 (4 hours), and M (1 hour), even though the 
duration of these phases are different in various cell lines [296]. In detail, G1 is the longest 
phase of the cell cycle, which represents the first step for cell duplicating. Altered expression of 
relative regulation factors like CKDs could influence the cell cycle phases, what can be 
analyzed by FACS. 
 
In WPMY-1 cells, up-regulated IGF-1 mRNA occurred here after exposure to 
MK-0677. This may suggest that a relationship between ghrelin system and 
IGF-1 exists in proliferation of prostate cells [300]. The relationship between the 
cellular proliferation and IGF-1 has been widely reported. For instance, in 
relation to growing children, activation of the ghrelin/ IGF-1 axis increases the 
body weights and stimulates longitudinal bone growth [301]. In prostate cell 
lines, IGF-1 signaling is indispensable to mediate estrogen-induced proliferation 
[302]. 
 
The results are in line with previous reports demonstrating a positive correlation 
between mRNA expression of IGF-1 and prostatic stromal cell growth. High 
  68 
expression of IGF-1 may explain the alteration of cell cycle. Increased IGF-1 
signaling has been reported to be involved in cell proliferation, cell survival and 
cell cycle.  
 
A crosstalk of IGF-1 and CDK2/CDK4 was observed in different cell types [303, 
304]. Growth factors, including IGF, EGF, TGF, FGF, have been reported to 
take part in the proliferation on different cell types [305]. Koshinaka et al. 
suggested that the GH-STAT5-IGF-1 axis existed in the plantaris muscle in a 
mice model and played an important role in preventing skeletal muscle atrophy 
[306]. Min et al. found that, by promoting nuclear localization of cyclin B/CDK1,  
IGF-I enhances activation of CDK1 kinase during G2/M in oligodendrocyte 
progenitor cells (OPCs) [307]. Furthermore, by means of stimulating of 
activation of PI3K/Akt/mTOR signaling, IGF-1 is essential for further 
progression of OPCs through G2/M.  
 
In WMPY-1 cells, MK-0677-induced expression of IGF-1 may effect on CDK2 
and CDK4, as suggested by RT-PCR. Subsequently, those CDKs, which are 
essential for promoting cell cycle progression, induce the proliferation of 
prostate stromal cells [305] (Figure 15). Thus, it appears obvious that the ghrelin 
system may be involved in the development of BPH/LUTS. IGF-1 signaling may 
be involved in ghrelin-induced proliferation in prostate cells.  
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Figure 15: The ghrelin system plays a role in the metabolic syndrome and alters the expression 
of growth factors via regulating the activation of CDK4 [295]. Subsequently, CDK4 combined 
with cyclin D partly activate E2F-dependent transcription, and CDK2 may promote the 
E2F-dependent transcription. These two stimulating inputs induce the acceleration of cell cycle. 
Finally, the proliferation of prostate stromal cell was increased by this network. 
 
5.4 PF-5190457 reduced the neurogenic and adrenergic 
contraction of prostate tissue 
According to the findings of this thesis, it was observed that an inverse ghrelin 
receptor agonist, PF-5190457, reduced EFS-induced contractions. EFS-induced 
smooth muscle contractions of prostate tissue are caused by adrenergic 
neurotransmission and subsequent activation of postsynaptic α1-adrenoceptors 
located on prostate smooth muscle cells [308]. Consequently, the effect of 
PF-5190457 on noradrenaline-induced contractions of prostate tissues was also 
examined. PF-5190457 reduced noradrenaline-induced contractions up to an 
noradrenaline-concentration of 30 µM, while an increased tone was observed at 
100 µM noradrenaline. These changes were significant after multivariate 
analysis. Notably however, the overall effect of PF-5190457 on 
noradrenaline-induced contractions was an inhibition, as shown by the p-value 
resulting from comparison of the whole groups. Any explanation, why an 
increased tone was observed at 100 µM remains speculation at this stage and on 
the basis of the available data. The noradrenaline-curves with and without 
PF-5910457 may point to a competitive antagonism of α1-adrenoceptors by 
PF-5910457, what would mean, that the whole effect is not caused by inverse 
agonism of GHSR, but antagonism of α1-adrenoceptors.  
 
Alternatively, these data may point to a cross-talk between GHSR and 
α1-adrenoceptors, which remains to be understood in detail. Thus, downstream 
cross-talk appears possible to explain this phenomenon. Most important from a 
clinical and translational view appears, that the overall and predominant effect of  
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PF-5910457 on noradrenaline-induced contraction was an inhibition [309]. 
PF-5910457 was introduced as a potent, selective ghrelin receptor inverse 
agonist and the first inverse GHSR agonist that translated to clinical 
development [310]. Based on pharmacologic research, PF-5170457 has a 
superior effect on ghrelin receptor and less off-target selectivity than other 
GHSR inhibitors [201]. However, the information of PF-5910457 on clinical 
translation is limited. PF-5910457 were provide by Pfizer and is a high affinity 
and selective ghrelin receptor inverse agonist (Kd  = 3 nM) [265]. A phase 1b 
human laboratory study suggest that heavy drinkers may benefit from 
administration of PF-5910457 [266]. This clinical study proved the safety and 
tolerability of PF-5190457. 
 
The findings of this thesis suggested that PF-5910457 inhibits α1-adrenergic 
contraction of prostate tissues, what is in line with the findings from a preceding 
thesis showing that ghrelin agonists enhance prostate contractions. Consequently, 
it may now be hypothesized that ghrelin management may improve LUTS 
suggestive to BPH. Nevertheless, the effect of PF-5910457 in vivo still needs to 
be confirmed in further studies, including animal models of BPH or with 
experimentally-induced LUTS.  
5.5 Translational aspects  
The findings suggest that ghrelin-induced proliferation of prostatic cells may 
take part in the development of BPH. However, we still need to explore the 
inverse agonists of ghrelin system in vivo. In order to benefit the patients who 
suffering with the LUTS suggestive to BPH, the effective medication or oral 
capsules are still needed.  
 
In principal, studies based on antagonists may be the right way. But: GHSR 
shows high intrinsic activity, so that in vivo (e.g. in models of obesity) pure 
antagonists will block GHSR-effects by only 50 % [260]. Therefore, the latest 
developments of ghrelin research are inverse agonists, which show higher 
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efficacy than pure antagonists [266]. PF-5190457 is an inverse GHSR agonist 
that inhibits constitutive activities of GHSR and reduce the activates of 
acyl-ghrelin, which has stronger effect than GHSR antagonists, including 
BIM28163 and JMV2959 [310]. The experiments in this thesis are the first 
addressing the effects of an inverse GHSR agonist, i. e. PF-5190457, on human 
prostate tissue. The main finding is that PF-5190457 may inhibit prostate smooth 
muscle contraction. Therefore PF-5190457 represents a promising compound, 
which may proceed to a novel pharmacotherapy for patients with LUTS 
suggestive to BPH. 
 
As another key finding of ghrelin agonist, that we observed MK-0677 improve 
the proliferation of prostate stromal cells. In prostate, ghrelin management may 
effect on the development of stromal cells growth. Prostate growth and smooth 
muscle contraction are main components for treatment of LUTS suggestive to 
BPH, and were regarded as two individual parts [311]. However, based on the 
current data suggesting that proliferation of prostate stromal cells and 
contraction of prostate smooth muscle are linked to metabolic hormone and its 
receptor. This may reveal the fact that treatment on disorder proliferation and 
contraction of prostate smooth muscle could rely on single compounds, which 
targets on the ghrelin system. Currently, based on the clinical studies, 
combination therapies are still required, which may be replaced by a single 
compound in the future [312].  
5.6 Conclusions 
The current results support the idea that the ghrelin system takes part in smooth 
muscle contraction and stromal growth in the hyperplastic human prostate. 
Considering low adherence to and low efficacy of medical LUTS therapies, 
other options with higher efficacy are necessary for the patients. The ghrelin 
system could be a promising target for the development of novel medications. 
Clinical trials using inverse ghrelin receptor inverse agonists appear possible and 
feasible.  
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Restricts of this thesis still exist. The thesis does not identify all the mechanisms 
by which ghrelin system effect on the proliferation of prostate cells and on 
contraction of prostate smooth muscle. It may be possible that ghrelin, through 
yet undescribed signaling pathway activates CDK2/CDK4 or IGF-1, leading to 
increased cyclin D1 expression on prostate stromal cells.  
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6. Conclusion 
The ghrelin system may be active in the prostate, as activation of ghrelin 
receptors promotes growth of stromal cells and inverse agonists reduces prostate 
smooth muscle contraction. Ghrelin agonist-induced prostate cell proliferation 
may be related to regulation of IGF-1 and cell cycle. The results of this thesis 
suggest that a treatment based on the ghrelin system may have the potential to 
influence LUTS suggestive to BPH. 
7. Summary 
Lower urinary tract symptoms (LUTS) suggestive of benign prostatic 
hyperplasia (BPH) are one of the most unpleasant issues for elderly male, while 
metabolic syndrome is considered to be an essential clinical risk factor of BPH. 
However, the efficacy of available medications for their treatment is limited. 
Recently, epidemiologic studies proved relationships between metabolic 
syndrome and LUTS suggestive to BPH. Other preliminary studies suggested 
that ghrelin system may take part in this linkage. 
 
By means of preclinical models, including human prostate tissue and cell culture, 
this thesis provides evidence that the metabolic hormone ghrelin increases the 
proliferation of prostate cells and, that a GHSR inverse agonist reduced prostate 
smooth muscle contraction. Results from different readouts confirmed a role of 
metabolic hormones in proliferation of prostate cells and regulation of cell cycle 
in BPH.  
 
Both processes, i. e. growth of stromal cells and smooth muscle contraction in 
the prostate, both contribute to urethral obstruction and LUTS in BPH. 
Considering the current findings, which suggested stromal cell proliferation and 
smooth muscle contraction by ghrelin, it appears possible that patients with 
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LUTS suggestive to BPH may profit from ghrelin management. These findings 
may provide a basis for subsequent clinical trials of ghrelin inverse agonist. 
8. Zusammenfassung 
Symptome des unteren Harntraktes (lower urinary tract symptoms, LUTS) auf 
Grund einer gutartigen Prostatavergrößerung (benigne Prostatahyperplasie, BPH) 
stellen von ihrer Wahrnehmung her eine der stärksten gesundheitlichen 
Belastungen bei älteren Männern dar. Das metabolische Syndrom hingegen wird 
als weniger belastend wahrgenommen, bildet aber einen erheblichen 
Risikofaktor für kardiovaskuläre Erkrankungen und die BPH. Die Effektivität 
von Medikamenten zur Behandlung der BPH ist deutlich begrenzt und 
unzureichend. Epidemiologische Studien wiesen kürzlich Zusammenhänge 
zwischen dem metabolischen Syndrom und LUTS bzw. der BPH nach. Andere 
vorläufige Ergebnisse wiesen auf eine mögliche Rolle des metabolischen 
Hormons Ghrelin in dieser Verknüpfung hin. 
 
In der vorliegenden Promotionsschrift werden Ergebnisse aus vorklinischen 
Untersuchungen präsentiert, welche eine Ghrelin-Rezeptor-induzierte 
Proliferation von Stromazellen der humanen Prostata (Zellkultur), sowie eine 
Abschwächung der glattmuskulären Kontraktion humaner Prostatagewebe 
(Organbad) durch einen inversen Ghrelin-Rezeptor Agonist belegen. Dabei 
bestätigen sich Ergebnisse aus verschiedenen Messmethoden (EdU- und 
Plate-Colony-Assay, mRNA-Expression verschiedener Marker, 
Durchflusszytometrische Messungen) gegenseitig, und weisen gemeinsam auf 
eine Ghrelin-induzierte Proliferation von Stromazellen der Prostata hin. 
 
Beide Prozesse, also das Wachstum von Stromazellen und die glattmuskuläre 
Kontraktion in der Prostata tragen bei einer BPH zu einer Verengung der 
Harnröhre, und so zu Beeinträchtigungen von Harnstrahl und Blasenentleerung 
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bei, was schließlich Miktionsbeschwerden verursacht. Daher legen die hier 
präsentierten Beobachtungen nahe, dass Patienten mit LUTS auf Grund einer 
BPH von einem medikamentösen Ghrelin-Management profitieren könnten. Die 
hier gemachten Beobachtungen könnten die Grundlage für nachfolgende 
klinische Studien mit inversen Ghrelin-Rezeptor-Agonisten bilden. 
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10. Abbreviation 
5-ARIs 5α-reductase inhibitors 
5-EdU 5-Ethynyl-deoxyuridine 
AG Acyl ghrelin 
ANOVA Analysis of variance 
ATCC American type culture collection 
ATP Adenosine 5’-triphosphate 
AUR Acute urinary retention  
BOO Bladder outlet obstruction 
BMI Body mass index 
BPE Benign prostate enlargement  
BPH Benign prostatic hyperplasia 
CaCl2•2H2O Calcium chloride dihydrate 
cAMP Cyclic adenosine monophosphate 
cGMP Cyclic guanosine monophosphate 
CCK Cell Counting Kit 
CDK Cyclin-dependent kinases 
CKD Chronic kidney disease 
CP Crossing points 
Ct Cycle threshold 
DAG Des-acyl ghrelin 
DAPI 4’,6’-diamidino-2-phenylindole-dihydrochloride 
DG Diacylglycerol 
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DHT Dihydrotestosterone 
DMSO Dimethyl sulfoxide 
DO Detrusor overactivity 
DTT Dithiothreitol 
EC50 Half maximal effective concentration 
ED Erectile dysfunction 
EjD Ejaculatory disorders 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
FACS Fluorescence-activated cell sorting 
FSC Forward scatter 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GOAT Ghrelin O acyl transferase 
GPCR G protein-coupled receptor 
GHSR Growth Hormone Secretagogue Receptor 
IC50 Half maximal inhibitory concentration 
IG Immunoglobulin superfamily 
IP3 Inositol 1,4,5-trisphosphate 
IPSS International Prostate Symptom Score 
KCl Potassium chloride 
KH Krebs Henseleit solution 
KH2PO4 Potassium hydrogen phosphate 
LIMKs LIM domain kinases 
LUTS Lower urinary tract symptoms 
MAPK Mitogen-activated protein kinase 
MetS Metabolic syndrome 
MgCl2 Magnesium chloride 
MgSO4•7H2O Magnesium sulfate heptahydrate 
MLC Myosin light chain 
NaCl Sodium chloride 
NaHCO3 Sodium bicarbonate 
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NSCs Neural sten cells 
OAB Overactive bladder 
OPCs Oligodendrocyte progenitor cells 
PBS Phosphate-buffered saline 
PDE Phosphodiesterase 
PDE5Is Phosphodiesterase 5 inhibitors 
PDEIs Phosphodiesterase inhibitors 
PI Propidium iodide 
PLC Phospholipase C 
PLK Pole-like kinases 
PK Protein kinases  
PKC Protein kinase C 
PSA Prostate specific antigen 
PVR Post-void residual 
Qmax Maximum flow rate 
RNA Ribonucleic acid 
RT-PCR real time polymerase chain reaction 
RP Radical prostatectomy 
RPMI 1640 Roswell Park Memorial Institute 1640 
SEM Standard error of the mean 
SeR Serenoa repens 
SFK Src family kinase 
STD Sexually transmitted diseases 
SRB Sulforhodamine B  
SSC Side scatter 
T2DM Type 2 diabetes mellitus 
TCA Trichloroacetic acid 
TURP Transurethral resection of prostate 
UI Urinary incontinence 
UR Urinary retention 
VEGF Vascular endothelial growth factor 
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VSMCs Vascular smooth muscle cells 
α1-blockers α1-Adrenoceptor antagonists 
β3-agonists Beta3 adrenoceptor agonists 
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